Uncoupling	B
protein-2	I
polymorphisms	O
in	O
type	O
2	O
diabetes	O
,	O
obesity	O
,	O
and	O
insulin	B
secretion	O
.	O

The	O
onset	O
of	O
type	O
2	O
diabetes	O
(	O
T2DM	O
)	O
is	O
preceded	O
by	O
obesity	O
,	O
insulin	B
resistance	O
,	O
and	O
impaired	O
beta	O
-	O
cell	O
function	O
.	O

Uncoupling	B
protein-2	I
(	O
UCP2	B
)	O
is	O
a	O
widely	O
expressed	O
inner	O
mitochondrial	O
membrane	O
protein	O
.	O

Common	O
polymorphisms	O
of	O
the	O
UCP2	B
gene	O
have	O
been	O
implicated	O
in	O
diabetes	O
,	O
in	O
obesity	O
,	O
and	O
with	O
changes	O
in	O
UCP2	B
mRNA	O
levels	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
common	O
UCP2	B
variants	O
influence	O
T2DM	O
susceptibility	O
in	O
four	O
parallel	O
studies	O
of	O
separate	O
populations	O
.	O

We	O
typed	O
the	O
-866	O
promoter	O
(	O
G	O
/	O
A	O
)	O
variant	O
,	O
a	O
nonsynonymous	O
(	O
Ala55Val	O
or	O
A55V	O
)	O
single	O
-	O
nucleotide	O
polymorphism	O
in	O
exon	O
4	O
,	O
and	O
a	O
45-nt	O
insertion	O
in	O
the	O
3'-untranslated	O
(	O
3'UTR	O
)	O
region	O
.	O

Study	O
populations	O
included	O
a	O
case	O
-	O
control	O
population	O
study	O
,	O
a	O
family	O
-	O
based	O
association	O
study	O
,	O
and	O
a	O
metabolic	O
study	O
of	O
individuals	O
who	O
had	O
been	O
characterized	O
for	O
insulin	B
sensitivity	O
and	O
secretion	O
.	O

To	O
evaluate	O
UCP2	B
mRNA	O
levels	O
,	O
we	O
examined	O
a	O
fourth	O
population	O
of	O
subjects	O
,	O
who	O
had	O
undergone	O
subcutaneous	O
fat	O
biopsy	O
.	O

All	O
three	O
variants	O
showed	O
a	O
trend	O
to	O
an	O
association	O
with	O
T2DM	O
(	O
P	O
=	O
0.05	O
to	O
0.07	O
)	O
in	O
the	O
population	O
but	O
not	O
the	O
family	O
-	O
based	O
association	O
study	O
.	O

The	O
3	O
'	O
insertion	O
/	O
deletion	O
(	O
3'UTR	O
I	O
/	O
D	O
)	O
variant	O
was	O
associated	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
,	O
P	O
=	O
0.035	O
)	O
among	O
nondiabetic	O
family	O
members	O
.	O

Haplotype	O
combinations	O
were	O
significantly	O
associated	O
with	O
BMI	O
(	O
P	O
=	O
0.028	O
)	O
,	O
triglyceride	O
levels	O
(	O
P	O
=	O
0.026	O
)	O
,	O
and	O
fasting	O
insulin	B
(	O
P	O
=	O
0.029	O
)	O
;	O
highest	O
values	O
for	O
the	O
three	O
traits	O
were	O
observed	O
in	O
individuals	O
with	O
the	O
heterozygous	O
combination	O
GVI	O
/	O
AVD	O
.	O

In	O
the	O
metabolic	O
study	O
,	O
all	O
three	O
variants	O
were	O
associated	O
with	O
an	O
index	O
of	O
beta	O
-	O
cell	O
compensation	O
for	O
insulin	B
sensitivity	O
(	O
disposition	O
index	O
)	O
,	O
particularly	O
in	O
interaction	O
with	O
family	O
membership	O
(	O
P	O
<	O
0.000001	O
)	O
.	O

Individuals	O
homozygous	O
for	O
the	O
-866	O
A	O
allele	O
had	O
decreased	O
adipose	O
mRNA	O
levels	O
relative	O
to	O
GG	O
homozygous	O
individuals	O
(	O
P	O
=	O
0.009	O
)	O
,	O
but	O
the	O
3'UTR	O
I	O
/	O
D	O
variant	O
had	O
no	O
impact	O
on	O
mRNA	O
levels	O
.	O

We	O
confirm	O
modest	O
effects	O
of	O
UCP2	B
variants	O
on	O
BMI	O
and	O
T2DM	O
and	O
show	O
significant	O
effects	O
on	O
insulin	B
secretion	O
in	O
interaction	O
with	O
family	O
-	O
specific	O
factors	O
.	O

However	O
,	O
the	O
associated	O
allele	O
and	O
the	O
effects	O
on	O
gene	O
expression	O
are	O
opposite	O
to	O
those	O
reported	O
previously	O
.	O

Association	O
of	O
TNF	B
-	I
beta	I
polymorphism	O
with	O
disease	O
severity	O
among	O
patients	O
infected	O
with	O
hepatitis	O
C	O
virus	O
.	O

The	O
pathogenesis	O
of	O
chronic	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
remains	O
unclear	O
.	O

Tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
is	O
alleged	O
to	O
contribute	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
HCV	O
infection	O
.	O

Single	O
nucleotide	O
polymorphism	O
in	O
TNF	B
-	I
alpha	I
and	O
-beta	O
genes	O
could	O
influence	O
the	O
outcome	O
of	O
HCV	O
infection	O
.	O

The	O
aim	O
was	O
to	O
study	O
single	O
nucleotide	O
polymorphism	O
in	O
TNF	B
-	I
alpha	I
promoter	O
region	O
and	O
Nco	O
I	O
polymorphisms	O
in	O
the	O
TNF	B
-	I
beta	I
gene	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C.	O
Fifty	O
-	O
two	O
patients	O
with	O
histologically	O
proven	O
chronic	O
hepatitis	O
,	O
who	O
had	O
raised	O
ALT	O
levels	O
(	O
>	O
1.5	O
x	O
ULN	O
)	O
and	O
were	O
HCV	O
RNA	O
positive	O
,	O
were	O
studied	O
.	O

Genotyping	O
of	O
-308	O
promoter	O
variant	O
of	O
TNF	B
-	I
alpha	I
was	O
performed	O
by	O
PCR	O
with	O
primers	O
that	O
incorporated	O
an	O
Nco	O
I	O
restriction	O
site	O
.	O

For	O
PCR	O
typing	O
of	O
the	O
TNF	B
-	I
beta	I
Nco	O
I	O
restriction	O
fragment	O
length	O
polymorphism	O
,	O
sequence	O
specific	O
primers	O
were	O
used	O
.	O

Polymorphism	O
in	O
the	O
TNF	B
-	I
alpha	I
G	O
/	O
G	O
,	O
G	O
/	O
A	O
and	O
A	O
/	O
A	O
allele	O
was	O
not	O
different	O
between	O
HCV	O
patients	O
and	O
healthy	O
controls	O
.	O

TNF	B
-	I
beta	I
A	O
/	O
A	O
allele	O
was	O
significantly	O
more	O
common	O
(	O
P	O
=	O
0.02	O
)	O
in	O
patients	O
(	O
28.8	O
%	O
)	O
as	O
compared	O
to	O
controls	O
(	O
12.8	O
%	O
)	O
,	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
for	O
TNF	B
-	I
beta	I
G	O
/	O
A	O
and	O
G	O
/	O
G	O
alleles	O
[	O
corrected	O
]	O
.	O

Nco	O
I	O
TNF	B
-	I
beta	I
A	O
/	O
A	O
was	O
strongly	O
associated	O
with	O
-308	O
TNF	B
-	I
alpha	I
G	O
/	O
GTNF	O
-	B
alpha	I
G	O
/	O
G	O
(	O
RR	O
of	O
HCV	O
persistence	O
=	O
4.9	O
)	O
,	O
indicating	O
possible	O
linkage	O
between	O
TNF	B
-	I
beta	I
A	O
/	O
A	O
and	O
TNF	B
-	I
alpha	I
G	O
/	O
G	O
allele	O
.	O

Patients	O
with	O
severe	O
hepatic	O
fibrosis	O
more	O
frequently	O
had	O
the	O
TNF	B
-	I
beta	I
A	O
/	O
A	O
allele	O
as	O
compared	O
to	O
patients	O
with	O
mild	O
disease	O
(	O
P	O
=	O
0.04	O
)	O
.	O

Immunogenetic	O
factors	O
,	O
such	O
as	O
single	O
nucleotide	O
polymorphisms	O
in	O
TNF	B
-	I
beta	I
(	O
A	O
/	O
A	O
allele	O
)	O
,	O
may	O
affect	O
the	O
natural	O
course	O
of	O
HCV	O
infection	O
,	O
in	O
particular	O
,	O
the	O
disease	O
progression	O
.	O

Larger	O
studies	O
including	O
cytokine	B
expression	O
profiles	O
are	O
needed	O
to	O
fully	O
understand	O
the	O
contribution	O
of	O
the	O
polymorphisms	O
described	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
hepatitis	O
C.	O

An	O
association	O
between	O
variants	O
in	O
the	O
IGF2	B
gene	O
and	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
:	O
interaction	O
between	O
genotype	O
and	O
epigenotype	O
.	O

Beckwith	O
-	O
Wiedemann	O
syndrome	O
(	O
BWS	O
)	O
is	O
a	O
fetal	O
overgrowth	O
disorder	O
involving	O
the	O
deregulation	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
IGF2	B
and	O
CDKN1C	B
,	O
in	O
the	O
imprinted	O
gene	O
cluster	O
on	O
chromosome	O
11p15.5	O
.	O

In	O
sporadic	O
BWS	O
cases	O
the	O
majority	O
of	O
patients	O
have	O
epimutations	O
in	O
this	O
region	O
.	O

Loss	O
of	O
imprinting	O
of	O
the	O
IGF2	B
gene	O
is	O
frequently	O
observed	O
in	O
BWS	O
,	O
as	O
is	O
reduced	O
CDKN1C	B
expression	O
related	O
to	O
loss	O
of	O
maternal	O
allele	O
-	O
specific	O
methylation	O
(	O
LOM	O
)	O
of	O
the	O
differentially	O
methylated	O
region	O
KvDMR1	B
.	O

The	O
causes	O
of	O
epimutations	O
are	O
unknown	O
,	O
although	O
recently	O
an	O
association	O
with	O
assisted	O
reproductive	O
technologies	O
has	O
been	O
described	O
.	O

To	O
date	O
the	O
only	O
genetic	O
mutations	O
described	O
in	O
BWS	O
are	O
in	O
the	O
CDKN1C	B
gene	O
.	O

In	O
order	O
to	O
screen	O
for	O
other	O
genetic	O
predispositions	O
to	O
BWS	O
,	O
the	O
conserved	O
sequences	O
between	O
human	O
and	O
mouse	O
differentially	O
methylated	O
regions	O
(	O
DMRs	O
)	O
of	O
the	O
IGF2	B
gene	O
were	O
analyzed	O
for	O
variants	O
.	O

Four	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
found	O
in	O
DMR0	O
(	O
T123C	O
,	O
G358A	O
,	O
T382	O
G	O
and	O
A402	O
G	O
)	O
which	O
occurred	O
in	O
three	O
out	O
of	O
16	O
possible	O
haplotypes	O
:	O
TGTA	O
,	O
CATG	O
and	O
CAGA	O
.	O

DNA	O
samples	O
from	O
a	O
cohort	O
of	O
sporadic	O
BWS	O
patients	O
and	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
DMR0	O
SNPs	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
the	O
frequency	O
of	O
the	O
CAGA	O
haplotype	O
and	O
a	O
significant	O
decrease	O
in	O
the	O
frequency	O
of	O
the	O
CATG	O
haplotype	O
in	O
the	O
patient	O
cohort	O
compared	O
to	O
controls	O
.	O

These	O
associations	O
were	O
still	O
significant	O
in	O
a	O
BWS	O
subgroup	O
with	O
KvDMR1	B
LOM	O
,	O
suggesting	O
that	O
the	O
G	O
allele	O
at	O
T382	O
G	O
SNP	O
(	O
CAGA	O
haplotype	O
)	O
is	O
associated	O
with	O
LOM	O
at	O
KvDMR1	B
.	O

This	O
indicates	O
either	O
a	O
genetic	O
predisposition	O
to	O
LOM	O
or	O
interactions	O
between	O
genotype	O
and	O
epigenotype	O
that	O
impinge	O
on	O
the	O
disease	O
phenotype	O
.	O

Association	O
of	O
tumor	B
necrosis	I
factor	I
polymorphisms	O
with	O
asthma	O
and	O
serum	O
total	O
IgE.	B
Tumor	B
necrosis	I
factors	I
(	O
TNF	B
;	O
TNFA	B
and	O
TNFB	B
)	O
are	O
major	O
pro	O
-	O
inflammatory	O
cytokines	O
that	O
are	O
thought	O
to	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
.	O

However	O
,	O
the	O
functions	O
of	O
genetic	O
polymorphisms	O
in	O
these	O
cytokines	O
have	O
not	O
been	O
thoroughly	O
examined	O
in	O
the	O
context	O
of	O
asthma	O
pathology	O
.	O

In	O
an	O
effort	O
to	O
discover	O
polymorphism	O
(	O
s	O
)	O
in	O
genes	O
whose	O
variant	O
(	O
s	O
)	O
have	O
been	O
implicated	O
in	O
asthma	O
phenotypes	O
,	O
we	O
examined	O
the	O
genetic	O
effects	O
of	O
TNF	B
(	O
TNFA	B
and	O
TNFB	B
)	O
polymorphisms	O
on	O
asthma	O
and	O
total	O
serum	O
IgE	B
level	O
.	O

Seven	O
common	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
TNF	B
genes	O
were	O
genotyped	O
in	O
a	O
Korean	O
asthma	O
cohort	O
(	O
asthmatics	O
n=550	O
,	O
normal	O
controls	O
n=171	O
)	O
.	O

Six	O
common	O
haplotypes	O
could	O
be	O
constructed	O
in	O
the	O
TNF	O
gene	O
cluster	O
due	O
to	O
very	O
strong	O
LD	O
between	O
TNFA	B
and	O
TNFB	B
,	O
located	O
13	O
kb	O
apart	O
on	O
chromosome	O
6p21	O
.	O

One	O
SNP	O
(	O
TNFA-308G	B
>	O
A	O
)	O
showed	O
a	O
significant	O
association	O
with	O
the	O
risk	O
of	O
asthma	O
(	O
P=0.0004	O
)	O
.	O

The	O
frequency	O
of	O
TNFA-308A	B
allele	O
-	O
containing	O
genotype	O
in	O
asthmatics	O
(	O
9.8	O
%	O
)	O
was	O
much	O
lower	O
than	O
that	O
in	O
normal	O
controls	O
(	O
22.9	O
%	O
)	O
.	O

The	O
protective	O
effects	O
of	O
this	O
polymorphism	O
on	O
asthma	O
were	O
also	O
evident	O
in	O
separated	O
subgroups	O
by	O
atopic	O
status	O
(	O
P=0.05	O
in	O
non	O
-	O
atopic	O
subjects	O
and	O
P=0.003	O
in	O
atopic	O
subjects	O
)	O
.	O

The	O
most	O
common	O
haplotype	O
of	O
the	O
TNF	B
gene	O
(	O
TNF	B
-	O
ht1	O
[	O
GGTCCGG	O
]	O
)	O
was	O
associated	O
with	O
total	O
serum	O
IgE	B
(	O
immunoglobulin	B
E	I
)	O
levels	O
in	O
asthma	O
patients	O
,	O
especially	O
in	O
non	O
-	O
atopic	O
patients	O
(	O
P=0.004	O
)	O
.	O

Genetic	O
variants	O
of	O
TNF	B
might	O
be	O
involved	O
in	O
development	O
of	O
asthma	O
and	O
total	O
serum	O
IgE	B
level	O
in	O
bronchial	O
asthma	O
patients	O
.	O

The	O
results	O
of	O
this	O
study	O
could	O
be	O
helpful	O
to	O
understand	O
the	O
function	O
of	O
important	O
TNF	B
genes	O
in	O
asthma	O
and	O
IgE	B
production	O
.	O

The	O
common	O
-866	O
G	O
/	O
A	O
polymorphism	O
in	O
the	O
promoter	O
of	O
uncoupling	B
protein	I
2	I
is	O
associated	O
with	O
increased	O
carbohydrate	O
and	O
decreased	O
lipid	O
oxidation	O
in	O
juvenile	O
obesity	O
.	O

Uncoupling	B
protein	I
(	I
UCP	I
)	I
2	I
is	O
a	O
member	O
of	O
the	O
mitochondrial	O
transporter	O
superfamily	O
that	O
uncouples	O
proton	O
entry	O
in	O
the	O
mitochondrial	O
matrix	O
from	O
ATP	O
synthesis	O
.	O

Although	O
its	O
physiological	O
role	O
remains	O
to	O
be	O
established	O
,	O
UCP2	B
is	O
considered	O
a	O
candidate	O
gene	O
for	O
association	O
with	O
energy	O
metabolism	O
and	O
obesity	O
.	O

A	O
common	O
promoter	O
polymorphism	O
,	O
-866	O
G	O
/	O
A	O
,	O
has	O
been	O
associated	O
with	O
increased	O
UCP2	B
gene	O
expression	O
and	O
middle	O
-	O
aged	O
adult	O
obesity	O
.	O

In	O
fact	O
,	O
our	O
analysis	O
of	O
296	O
juvenile	O
obese	O
and	O
568	O
nonobese	O
control	O
subjects	O
revealed	O
no	O
difference	O
in	O
the	O
prevalence	O
of	O
this	O
polymorphism	O
.	O

Insulin	B
and	O
glucose	O
response	O
to	O
oral	O
glucose	O
was	O
comparable	O
across	O
the	O
-866	O
genotypes	O
.	O

Metabolic	O
studies	O
in	O
147	O
of	O
these	O
juvenile	O
obese	O
subjects	O
showed	O
that	O
homozygosity	O
for	O
the	O
UCP2	B
promoter	O
variant	O
A	O
was	O
associated	O
with	O
important	O
changes	O
in	O
energy	O
metabolism	O
compared	O
with	O
other	O
genotypes	O
,	O
i.e.	O
,	O
a	O
34	O
%	O
increase	O
of	O
carbohydrate	O
oxidation	O
(	O
94	O
+	O
/-	O
10	O
vs.	O
70	O
+	O
/-	O

3	O
mg.min	O
(	O
-1	O
)	O
.m	O
(	O
-2	O
)	O
,	O
P	O
=	O
0.004	O
)	O
and	O
a	O
23	O
%	O
decrease	O
of	O
lipid	O
oxidation	O
(	O
26	O
+	O
/-	O

3	O
vs.	O
34	O
+	O
/-	O

1	O
mg.min	O
(	O
-1	O
)	O
.m	O
(	O
-2	O
)	O
,	O
P	O
=	O
0.03	O
)	O
.	O

Therefore	O
,	O
the	O
juvenile	O
obese	O
subjects	O
who	O
are	O
homozygous	O
for	O
the	O
A	O
variant	O
have	O
an	O
increased	O
ratio	O
(	O
3.6	O
+	O
/-	O

1.2	O
)	O
of	O
calories	O
derived	O
from	O
carbohydrates	O
to	O
those	O
from	O
lipids	O
compared	O
with	O
G	O
/	O
A	O
or	O
G	O
/	O
G	O
obese	O
children	O
(	O
1.4	O
+	O
/-	O

0.2	O
,	O
P	O
=	O
0.003	O
)	O
,	O
suggesting	O
a	O
role	O
for	O
UCP2	B
in	O
the	O
partitioning	O
of	O
metabolic	O
fuels	O
.	O

Ghrelin	B
receptor	I
gene	O
:	O
identification	O
of	O
several	O
sequence	O
variants	O
in	O
extremely	O
obese	O
children	O
and	O
adolescents	O
,	O
healthy	O
normal	O
-	O
weight	O
and	O
underweight	O
students	O
,	O
and	O
children	O
with	O
short	O
normal	O
stature	O
.	O

GH	B
secretagogue	I
receptor	I
(	O
GHSR	B
,	O
ghrelin	B
receptor	I
)	O
is	O
involved	O
in	O
regulation	O
of	O
body	O
weight	O
and	O
GH	B
secretion	O
.	O

We	O
initially	O
analyzed	O
two	O
single	O
-	O
nucleotide	O
polymorphisms	O
of	O
the	O
GHSR	B
in	O
up	O
to	O
184	O
extremely	O
obese	O
children	O
and	O
adolescents	O
and	O
up	O
to	O
184	O
healthy	O
underweight	O
students	O
.	O

The	O
frequency	O
of	O
the	O
171	O
T	O
allele	O
of	O
rs495225	O
was	O
higher	O
in	O
our	O
obese	O
samples	O
(	O
75.0	O
%	O
)	O
than	O
in	O
the	O
underweight	O
individuals	O
(	O
70.2	O
%	O
;	O
nominal	O
P	O
=	O
0.14	O
)	O
.	O

This	O
trend	O
could	O
not	O
be	O
substantiated	O
in	O
an	O
additional	O
association	O
study	O
in	O
270	O
obese	O
and	O
145	O
underweight	O
and	O
normal	O
weight	O
individuals	O
and	O
in	O
a	O
transmission	O
disequilibrium	O
test	O
based	O
on	O
387	O
obesity	O
trios	O
(	O
transmission	O
rate	O
of	O
171	O
T	O
,	O
51.8	O
%	O
;	O
nominal	O
P	O
=	O
0.53	O
)	O
.	O

Additionally	O
,	O
the	O
coding	O
region	O
of	O
GHSR	B
was	O
systematically	O
screened	O
,	O
and	O
seven	O
sequence	O
variants	O
were	O
identified	O
in	O
93	O
obese	O
,	O
96	O
normal	O
weight	O
,	O
and	O
94	O
underweight	O
individuals	O
and	O
43	O
children	O
with	O
short	O
normal	O
stature	O
(	O
SNS	O
)	O
.	O

Five	O
silent	O
single	O
-	O
nucleotide	O
polymorphisms	O
showed	O
similar	O
genotype	O
frequencies	O
in	O
the	O
different	O
weight	O
groups	O
and	O
SNS	O
children	O
(	O
all	O
nominal	O
P	O
>	O
0.3	O
)	O
.	O

Two	O
novel	O
missense	O
variants	O
were	O
detected	O
only	O
in	O
one	O
obese	O
carrier	O
and	O
one	O
SNS	O
child	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
we	O
did	O
not	O
obtain	O
conclusive	O
evidence	O
for	O
an	O
involvement	O
of	O
the	O
ghrelin	B
receptor	I
gene	O
in	O
body	O
weight	O
regulation	O
or	O
SNS	O
in	O
our	O
study	O
groups	O
.	O

Cytotoxic	B
T	I
lymphocyte	I
-	I
associated	I
molecule-4	I
polymorphism	O
and	O
relapse	O
of	O
Graves	O
'	O
hyperthyroidism	O
after	O
antithyroid	O
withdrawal	O
.	O

We	O
studied	O
the	O
A	O
/	O
G	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
at	O
position	O
49	O
in	O
exon	O
1	O
of	O
the	O
cytotoxic	B
T	I
lymphocyte	I
-	I
associated	I
molecule-4	I
gene	O
in	O
148	O
Chinese	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
patients	O
and	O
171	O
controls	O
.	O

Our	O
primary	O
aim	O
was	O
to	O
test	O
for	O
the	O
association	O
of	O
this	O
SNP	O
with	O
the	O
relapse	O
of	O
the	O
hyperthyroidism	O
after	O
antithyroid	O
withdrawal	O
.	O

Our	O
secondary	O
aim	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
GD	O
patients	O
and	O
controls	O
according	O
to	O
the	O
SNP	O
genotypes	O
.	O

All	O
GD	O
patients	O
were	O
divided	O
into	O
the	O
following	O
three	O
groups	O
according	O
to	O
the	O
time	O
of	O
relapse	O
after	O
drug	O
discontinuation	O
:	O
group	O
1	O
,	O
early	O
relapse	O
within	O
9	O
months	O
;	O
group	O
2	O
,	O
relapse	O
between	O
10	O
and	O
36	O
months	O
;	O
and	O
group	O
3	O
,	O
relapse	O
3	O
or	O
more	O
years	O
after	O
discontinuation	O
of	O
treatment	O
.	O

There	O
was	O
a	O
significant	O
difference	O
of	O
genotype	O
frequencies	O
(	O
P	O
<	O
0.001	O
)	O
and	O
allele	O
frequencies	O
(	O
P	O
<	O
0.001	O
)	O
among	O
the	O
three	O
groups	O
of	O
patients	O
.	O

The	O
frequency	O
of	O
the	O
G	O
/	O
G	O
genotype	O
decreased	O
from	O
79	O
%	O
to	O
64	O
%	O
and	O
39	O
%	O
in	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
respectively	O
.	O

Compared	O
with	O
controls	O
,	O
a	O
strong	O
association	O
(	O
P	O
<	O
0.001	O
)	O
of	O
G	O
allele	O
was	O
found	O
for	O
group	O
1	O
,	O
and	O
moderate	O
significance	O
(	O
P	O
=	O
0.04	O
)	O
was	O
found	O
for	O
group	O
2	O
,	O
but	O
no	O
association	O
(	O
P	O
=	O
0.33	O
)	O
was	O
found	O
for	O
group	O
3	O
.	O

At	O
the	O
end	O
of	O
treatment	O
,	O
the	O
percentage	O
of	O
patients	O
with	O
persistent	O
TSH	B
-	I
receptor	I
antibody	O
was	O
statistically	O
different	O
(	O
A	O
/	O
A	O
,	O
9.0	O
%	O
;	O
A	O
/	O
G	O
,	O
20.8	O
%	O
;	O
G	O
/	O
G	O
,	O
45.5	O
%	O
;	O
P	O
=	O
0.004	O
)	O
.	O

Using	O
3	O
yr	O
as	O
the	O
cutoff	O
point	O
for	O
multivariate	O
logistic	O
regression	O
analysis	O
,	O
we	O
found	O
that	O
the	O
G	O
/	O
G	O
genotype	O
(	O
adjusted	O
odds	O
ratio	O
,	O
3.1	O
compared	O
with	O
A	O
/	O
G	O
plus	O
A	O
/	O
A	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.3	O
-	O
7.1	O
)	O
,	O
larger	O
goiter	O
size	O
at	O
the	O
end	O
of	O
treatment	O
,	O
and	O
positive	O
TSH	B
-	I
receptor	I
antibody	O
at	O
the	O
end	O
of	O
treatment	O
were	O
independent	O
risk	O
factors	O
of	O
recurrence	O
.	O

We	O
conclude	O
that	O
the	O
A	O
/	O
G	O
polymorphism	O
of	O
the	O
cytotoxic	B
T	I
lymphocyte	I
-	I
associated	I
molecule-4	I
gene	O
affects	O
the	O
progress	O
of	O
GD	O
.	O

The	O
G	O
/	O
G	O
genotype	O
is	O
associated	O
with	O
poor	O
outcome	O
.	O

Association	O
of	O
the	O
Pro12Ala	O
and	O
C1431	O
T	O
variants	O
of	O
PPARG	B
and	O
their	O
haplotypes	O
with	O
susceptibility	O
to	O
Type	O
2	O
diabetes	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
The	O
Pro12Ala	O
polymorphism	O
of	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
(	I
PPAR	I
)	I
gamma	I
has	O
been	O
consistently	O
associated	O
with	O
Type	O
2	O
diabetes	O
.	O

The	O
rare	O
Ala12	O
variant	O
is	O
estimated	O
to	O
reduce	O
the	O
risk	O
of	O
developing	O
Type	O
2	O
diabetes	O
by	O
20	O
percent	O
.	O

This	O
variant	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
another	O
common	O
variant	O
,	O
T1431	O
.	O

Both	O
have	O
opposing	O
associations	O
with	O
body	O
weight	O
.	O

We	O
therefore	O
examined	O
the	O
association	O
of	O
specific	O
haplotypes	O
marked	O
by	O
these	O
two	O
variants	O
with	O
susceptibility	O
to	O
Type	O
2	O
diabetes	O
.	O

METHODS	O
:	O
We	O
determined	O
the	O
PPARG	B
genotype	O
of	O
a	O
large	O
Scottish	O
cohort	O
of	O
Type	O
2	O
diabetic	O
patients	O
(	O
n=1997	O
)	O
and	O
compared	O
allele	O
frequencies	O
with	O
a	O
cohort	O
of	O
local	O
children	O
(	O
n=2444	O
)	O
and	O
a	O
middle	O
-	O
aged	O
,	O
population	O
-	O
based	O
cohort	O
from	O
Scotland	O
(	O
n=1061	O
)	O
.	O

RESULTS	O
:	O
Frequency	O
of	O
the	O
Ala12	O
allele	O
was	O
slightly	O
lower	O
in	O
the	O
Type	O
2	O
diabetic	O
cohort	O
than	O
in	O
the	O
children	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=0.91	O
,	O
p=0.1	O
]	O
.	O

In	O
contrast	O
,	O
the	O
Ala12	O
variant	O
was	O
under	O
-	O
represented	O
in	O
the	O
Type	O
2	O
diabetic	O
population	O
when	O
compared	O
with	O
similarly	O
aged	O
non	O
-	O
diabetic	O
adults	O
(	O
OR=0.74	O
,	O
p=0.0006	O
)	O
.	O

When	O
the	O
Ala12	O
variant	O
was	O
on	O
a	O
haplotype	O
not	O
bearing	O
the	O
1431	O
T	O
variant	O
,	O
it	O
conferred	O
greater	O
protection	O
(	O
OR=0.66	O
,	O
p=0.003	O
)	O
.	O

However	O
,	O
when	O
it	O
was	O
present	O
in	O
haplotypes	O
containing	O
the	O
1431	O
T	O
variant	O
(	O
70	O
%	O
of	O
Ala12	O
carriers	O
)	O
,	O
this	O
protection	O
was	O
absent	O
(	O
OR=0.99	O
,	O
p=0.94	O
)	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
We	O
replicated	O
the	O
finding	O
that	O
the	O
Ala12	O
variant	O
of	O
PPARgamma	B
affords	O
protection	O
from	O
Type	O
2	O
diabetes	O
,	O
and	O
suggest	O
that	O
this	O
protection	O
is	O
modulated	O
by	O
additional	O
common	O
variation	O
at	O
the	O
PPARG	B
locus	O
.	O

Associations	O
between	O
breast	O
cancer	O
susceptibility	O
gene	O
polymorphisms	O
and	O
clinicopathological	O
features	O
.	O

PURPOSE	O
:	O
Genetic	O
polymorphisms	O
may	O
affect	O
not	O
only	O
cancer	O
development	O
but	O
also	O
cancer	O
progression	O
,	O
and	O
as	O
a	O
result	O
could	O
influence	O
cancer	O
phenotypes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
relationship	O
between	O
breast	O
cancer	O
susceptibility	O
gene	O
polymorphisms	O
and	O
clinicopathological	O
features	O
.	O

Experimental	O
Design	O
:	O
We	O
genotyped	O
664	O
Korean	O
primary	O
breast	O
cancer	O
patients	O
for	O
17	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
nine	O
genes	O
,	O
using	O
a	O
high	O
-	O
throughput	O
SNP	O
scoring	O
method	O
.	O

RESULTS	O
:	O
CYP1A1	B
codon	O
462	O
Ile	O
/	O
Val	O
or	O
Val	O
/	O
Val	O
variants	O
and	O
the	O
CYP1B1	B
codon	O
432	O
Leu	O
/	O
Val	O
variant	O
were	O
found	O
more	O
in	O
breast	O
cancer	O
patients	O
<	O
/=35	O
years	O
of	O
age	O
at	O
onset	O
than	O
the	O
common	O
homozygote	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
,	O
1.6	O
and	O
1.7	O
,	O
respectively	O
]	O
.	O

In	O
combination	O
analysis	O
of	O
these	O
two	O
SNPs	O
,	O
the	O
OR	O
was	O
1.9	O
when	O
one	O
of	O
them	O
was	O
heterozygous	O
or	O
a	O
rare	O
homozygous	O
form	O
,	O
and	O
increased	O
to	O
2.3	O
when	O
both	O
were	O
variants	O
(	O
P	O
=	O
0.006	O
)	O
.	O

Cases	O
with	O
Ile	O
/	O
Val	O
at	O
CYP1A1	B
codon	O
462	O
were	O
2.6-fold	O
and	O
those	O
with	O
Val	O
/	O
Val	O
were	O
5.1-fold	O
more	O
likely	O
to	O
have	O
first	O
-	O
degree	O
relatives	O
with	O
breast	O
cancer	O
than	O
those	O
with	O
Ile	O
/	O
Ile	O
(	O
P	O
=	O
0.002	O
)	O
.	O

In	O
the	O
haplotype	O
study	O
of	O
BRCA1	B
,	O
the	O
2430C	O
/	O
2731T	O
/	O
3667G	O
/	O
4427C	O
/	O
4956	O
G	O
homozygote	O
showed	O
less	O
estrogen	O
receptor	O
negativity	O
than	O
the	O
most	O
common	O
diplotype	O
(	O
OR	O
,	O
0.5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.26	O
-	O
0.94	O
)	O
.	O

TP53	B
codon	O
72	O
Arg	O
/	O
Pro	O
or	O
Pro	O
/	O
Pro	O
variants	O
were	O
associated	O
with	O
negative	O
axillary	O
lymph	O
node	O
status	O
(	O
OR	O
,	O
0.7	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.49	O
-	O
0.94	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
polymorphisms	O
of	O
some	O
selected	O
breast	O
cancer	O
susceptibility	O
genes	O
are	O
associated	O
with	O
the	O
clinicopathological	O
phenotypes	O
of	O
breast	O
cancer	O
.	O

Collagen	B
type	I
I	I
alpha2	I
(	O
COL1A2	B
)	O
is	O
the	O
susceptible	O
gene	O
for	O
intracranial	O
aneurysms	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
collagen	B
alpha2	I
(	I
I	I
)	I
gene	O
(	O
COL1A2	B
)	O
on	O
chromosome	O
7q22.1	O
,	O
a	O
positional	O
and	O
functional	O
candidate	O
for	O
intracranial	O
aneurysm	O
(	O
IA	O
)	O
,	O
was	O
extensively	O
screened	O
for	O
susceptibility	O
in	O
Japanese	O
IA	O
patients	O
.	O

METHODS	O
:	O
Twenty	O
-	O
one	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
COL1A2	B
were	O
genotyped	O
in	O
genomic	O
DNA	O
from	O
260	O
IA	O
patients	O
(	O
including	O
115	O
familial	O
cases	O
)	O
(	O
mean	O
age	O
,	O
59.9	O
years	O
)	O
and	O
293	O
controls	O
(	O
mean	O
age	O
,	O
61.6	O
years	O
)	O
.	O

Differences	O
in	O
allelic	O
and	O
genotypic	O
frequencies	O
between	O
the	O
patients	O
and	O
controls	O
were	O
evaluated	O
with	O
the	O
chi	O
(	O
2	O
)	O
test	O
.	O

Circular	O
dichroism	O
spectrometry	O
was	O
monitored	O
with	O
collagen	O
-	O
related	O
peptides	O
that	O
mimic	O
triple	O
-	O
helical	O
models	O
of	O
type	B
I	I
collagen	I
with	O
Ala-459	O
and	O
Pro-459	O
to	O
estimate	O
the	O
conformation	O
and	O
stability	O
of	O
alterations	O
.	O

RESULTS	O
:	O
Significant	O
genotypic	O
association	O
in	O
the	O
dominant	O
model	O
was	O
observed	O
between	O
an	O
exonic	O
SNP	O
of	O
COL1A2	B
and	O
familial	O
IA	O
patients	O
(	O
chi	O
(	O
2	O
)	O
=11.08	O
;	O
df=1	O
;	O
P=0.00087	O
;	O
odds	O
ratio=3.19	O
;	O
95	O
%	O
CI	O
,	O
2.22	O
to	O
6.50	O
)	O
.	O

This	O
SNP	O
induces	O
Ala	O
to	O
Pro	O
substitution	O
at	O
amino	O
acid	O
459	O
,	O
located	O
on	O
a	O
triple	O
-	O
helical	O
domain	O
.	O

Circular	O
dichroism	O
spectra	O
showed	O
that	O
the	O
Pro-459	O
peptide	O
had	O
a	O
higher	O
thermal	O
stability	O
than	O
the	O
Ala-459	O
peptide	O
.	O

CONCLUSIONS	O
:	O
The	O
variant	O
of	O
COL1A2	B
could	O
be	O
a	O
genetic	O
risk	O
factor	O
for	O
IA	O
patients	O
with	O
family	O
history	O
.	O

Uncoupling	B
protein	I
2	I
promoter	O
polymorphism	O
-866G	O
/	O
A	O
affects	O
its	O
expression	O
in	O
beta	O
-	O
cells	O
and	O
modulates	O
clinical	O
profiles	O
of	O
Japanese	O
type	O
2	O
diabetic	O
patients	O
.	O

Common	O
uncoupling	B
protein	I
2	I
(	O
UCP2	B
)	O
promoter	O
polymorphism	O
-866G	O
/	O
A	O
is	O
reported	O
to	O
be	O
associated	O
with	O
its	O
expression	O
in	O
adipose	O
tissue	O
and	O
the	O
risk	O
of	O
obesity	O
in	O
Caucasians	O
.	O

On	O
the	O
other	O
hand	O
,	O
several	O
studies	O
suggested	O
that	O
UCP2	B
expression	O
in	O
beta	O
-	O
cells	O
is	O
an	O
important	O
determinant	O
of	O
insulin	B
secretion	O
.	O

In	O
the	O
Japanese	O
population	O
,	O
morbid	O
obesity	O
is	O
very	O
rare	O
,	O
and	O
insulin	B
secretion	O
capacity	O
is	O
relatively	O
low	O
as	O
compared	O
with	O
Caucasians	O
.	O

Because	O
UCP2	B
would	O
link	O
to	O
insulin	B
secretion	O
and	O
obesity	O
,	O
it	O
might	O
explain	O
this	O
ethnic	O
difference	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
UCP2	B
promoter	O
with	O
the	O
A	O
allele	O
showed	O
higher	O
promoter	O
activity	O
in	O
the	O
INS-1	O
beta	O
-	O
cell	O
line	O
.	O

The	O
frequency	O
of	O
the	O
A	O
allele	O
is	O
higher	O
in	O
our	O
Japanese	O
study	O
than	O
that	O
in	O
Caucasians	O
.	O

Type	O
2	O
diabetic	O
patients	O
with	O
the	O
A	O
allele	O
need	O
insulin	B
therapy	O
earlier	O
and	O
showed	O
higher	O
frequency	O
of	O
insulin	B
treatment	O
.	O

Moreover	O
glucose	O
-	O
induced	O
early	O
insulin	B
secretion	O
is	O
significantly	O
lower	O
in	O
patients	O
with	O
the	O
A	O
allele	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
allele	O
frequency	O
between	O
obese	O
and	O
lean	O
type	O
2	O
diabetic	O
patients	O
.	O

In	O
conclusion	O
,	O
UCP2	B
promoter	O
polymorphism	O
-866G	O
/	O
A	O
does	O
not	O
affect	O
obesity	O
in	O
Japanese	O
type	O
2	O
diabetic	O
patients	O
but	O
affects	O
its	O
transcription	O
in	O
beta	O
-	O
cells	O
and	O
modulates	O
glucose	O
-	O
induced	O
insulin	B
secretion	O
and	O
eventually	O
insulin	B
requirement	O
in	O
Japanese	O
type	O
2	O
diabetic	O
patients	O
.	O

Higher	O
A	O
allele	O
frequency	O
in	O
the	O
Japanese	O
population	O
might	O
partly	O
explain	O
the	O
ethnic	O
difference	O
of	O
insulin	B
secretion	O
capacity	O
.	O

Association	O
of	O
TAP2	B
gene	O
polymorphisms	O
in	O
Chinese	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
the	O
polymorphism	O
of	O
transporters	O
associated	O
with	O
antigen	O
processing	O
(	O
TAP1	B
/	O
TAP2	B
)	O
genes	O
and	O
rheumatoid	O
arthritis	O
in	O
Chinese	O
patients	O
.	O

A	O
total	O
of	O
100	O
RA	O
patients	O
and	O
99	O
healthy	O
control	O
subjects	O
were	O
enrolled	O
.	O

Analyses	O
with	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
based	O
restrictions	O
were	O
used	O
to	O
identify	O
the	O
polymorphisms	O
of	O
the	O
TAP1	B
and	O
TAP2	B
genes	O
,	O
which	O
were	O
mapped	O
on	O
chromosome	O
6	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
distribution	O
of	O
the	O
TAP2	B
gene	O
codon	O
565	O
polymorphism	O
frequency	O
between	O
the	O
RA	O
patients	O
and	O
healthy	O
control	O
subjects	O
(	O
p<0.001	O
)	O
.	O

The	O
odds	O
ratio	O
for	O
the	O
risk	O
of	O
the	O
'	O
A	O
'	O
allele	O
in	O
RA	O
patients	O
was	O
1.60	O
(	O
95	O
%	O
CI	O
:	O
0.82	O
-	O
2.92	O
)	O
.	O

No	O
statistical	O
associations	O
in	O
the	O
distribution	O
of	O
the	O
TAP1	B
gene	O
polymorphism	O
frequency	O
were	O
found	O
between	O
RA	O
patients	O
and	O
controls	O
.	O

There	O
were	O
some	O
physical	O
links	O
found	O
between	O
TAP1	B
/	O
TAP2	B
gene	O
polymorphism	O
loci	O
.	O

However	O
,	O
there	O
was	O
no	O
linkage	O
observed	O
from	O
TAP1	B
/	O
TAP2	B
gene	O
polymorphisms	O
and	O
HLA	O
-	O
DRB1	O
*	O
04	O
between	O
RA	O
patients	O
and	O
healthy	O
controls	O
.	O

We	O
concluded	O
that	O
the	O
TAP2	B
gene	O
codon	O
565	O
'	O
A	O
'	O
allele	O
was	O
associated	O
with	O
RA	O
in	O
Chinese	O
patients	O
in	O
Taiwan	O
.	O

Individuals	O
possessing	O
the	O
'	O
A	O
'	O
allele	O
had	O
a	O
higher	O
incidence	O
of	O
RA	O
.	O

A	O
lack	O
of	O
association	O
of	O
TAP1	B
gene	O
polymorphisms	O
between	O
RA	O
patients	O
and	O
healthy	O
individuals	O
was	O
noted	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
genetic	O
evidence	O
that	O
TAP2	B
gene	O
codon	O
565	O
polymorphism	O
may	O
play	O
a	O
role	O
in	O
RA	O
.	O

Tests	O
of	O
linkage	O
and/or	O
association	O
of	O
the	O
LEPR	B
gene	O
polymorphisms	O
with	O
obesity	O
phenotypes	O
in	O
Caucasian	O
nuclear	O
families	O
.	O

Genetic	O
variations	O
in	O
the	O
leptin	B
receptor	I
(	O
LEPR	B
)	O
gene	O
have	O
been	O
conceived	O
to	O
affect	O
body	O
weight	O
in	O
general	O
populations	O
.	O

In	O
this	O
study	O
,	O
using	O
the	O
tests	O
implemented	O
in	O
the	O
statistical	O
package	O
QTDT	O
,	O
we	O
evaluated	O
association	O
and/or	O
linkage	O
of	O
the	O
LEPR	B
gene	O
with	O
obesity	O
phenotypes	O
in	O
a	O
large	O
sample	O
comprising	O
1,873	O
subjects	O
from	O
405	O
Caucasian	O
nuclear	O
families	O
.	O

Obesity	O
phenotypes	O
tested	O
include	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
fat	O
mass	O
,	O
percentage	O
fat	O
mass	O
(	O
PFM	O
)	O
,	O
and	O
lean	O
mass	O
,	O
with	O
the	O
latter	O
three	O
measured	O
by	O
dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DXA	O
)	O
.	O

Three	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
namely	O
Lys109Arg	O
(	O
A	O
/	O
G	O
)	O
,	O
Lys656Asn	O
(	O
G	O
/	O
C	O
)	O
,	O
Pro1019Pro	O
(	O
G	O
/	O
A	O
)	O
,	O
in	O
the	O
LEPR	B
gene	O
were	O
analyzed	O
.	O

Significant	O
linkage	O
disequilibrium	O
(	O
0.394	O
<	O
or	O
=	O
|D'|	O
<	O
or	O
=	O
0.688	O
,	O
P	O
<	O
0.001	O
)	O
was	O
observed	O
between	O
pairs	O
of	O
the	O
three	O
SNPs	O
.	O

No	O
significant	O
population	O
stratification	O
was	O
found	O
for	O
any	O
SNP	O
/	O
phenotype	O
.	O

In	O
single	O
-	O
locus	O
analyses	O
,	O
evidence	O
of	O
association	O
was	O
observed	O
for	O
Lys656Asn	O
with	O
lean	O
mass	O
(	O
P	O
=	O
0.002	O
)	O
and	O
fat	O
mass	O
(	O
P	O
=	O
0.015	O
)	O
.	O

The	O
contribution	O
of	O
this	O
polymorphism	O
to	O
the	O
phenotypic	O
variation	O
of	O
lean	O
mass	O
and	O
fat	O
mass	O
was	O
2.63	O
%	O
and	O
1.15	O
%	O
,	O
respectively	O
.	O

Subjects	O
carrying	O
allele	O
G	O
at	O
the	O
Lys656Asn	O
site	O
had	O
,	O
on	O
average	O
,	O
3.16	O
%	O
higher	O
lean	O
mass	O
and	O
2.71	O
%	O
higher	O
fat	O
mass	O
than	O
those	O
without	O
it	O
.	O

In	O
the	O
analyses	O
for	O
haplotypes	O
defined	O
by	O
the	O
three	O
SNPs	O
,	O
significant	O
associations	O
were	O
detected	O
between	O
haplotype	O
GCA	O
(	O
P	O
=	O
0.005	O
)	O
and	O
lean	O
mass	O
.	O

In	O
addition	O
,	O
marginally	O
significant	O
evidence	O
of	O
association	O
was	O
observed	O
for	O
this	O
haplotype	O
with	O
fat	O
mass	O
(	O
P	O
=	O
0.012	O
)	O
.	O

No	O
statistically	O
significant	O
linkage	O
was	O
found	O
,	O
largely	O
due	O
to	O
the	O
limited	O
power	O
of	O
the	O
linkage	O
approach	O
to	O
detect	O
small	O
genetic	O
effects	O
in	O
our	O
data	O
sets	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
LEPR	B
gene	O
polymorphisms	O
contribute	O
to	O
variation	O
in	O
obesity	O
phenotypes	O
.	O

The	O
Arg753GLn	O
polymorphism	O
of	O
the	O
human	O
toll	B
-	I
like	I
receptor	I
2	I
gene	O
in	O
tuberculosis	O
disease	O
.	O

Toll	B
-	I
like	I
receptor	I
2	I
(	O
TLR2	B
)	O
)	O
,	O
a	O
member	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
recognition	O
of	O
,	O
and	O
subsequent	O
immune	O
response	O
activation	O
against	O
,	O
mycobacteria	O
.	O

The	O
genetic	O
polymorphism	O
of	O
TLR2	B
(	O
arginine	O
to	O
glutamine	O
substitution	O
at	O
residue	O
753	O
(	O
Arg753Gln	O
)	O
)	O
has	O
been	O
associated	O
with	O
a	O
negative	O
influence	O
on	O
TLR2	B
function	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
determine	O
the	O
innate	O
host	O
response	O
to	O
mycobacteria	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
Arg753Gln	O
single	O
nucleotide	O
polymorphism	O
of	O
the	O
TLR2	B
gene	O
in	O
tuberculosis	O
(	O
TB	O
)	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

A	O
retrospective	O
case	O
/	O
control	O
study	O
was	O
carried	O
out	O
.	O

The	O
Arg753Gln	O
polymorphism	O
of	O
the	O
TLR2	B
gene	O
was	O
studied	O
in	O
151	O
TB	O
patients	O
compared	O
to	O
116	O
ethnically	O
and	O
age	O
-	O
matched	O
healthy	O
control	O
subjects	O
.	O

The	O
TLR2	B
polymorphism	O
(	O
adenine	O
(	O
A	O
)	O
allele	O
)	O
was	O
observed	O
in	O
17.9	O
and	O
7.7	O
%	O
of	O
TB	O
patients	O
and	O
controls	O
,	O
respectively	O
.	O

When	O
the	O
ratios	O
of	O
the	O
three	O
genotypes	O
were	O
compared	O
between	O
the	O
two	O
groups	O
,	O
the	O
AA	O
genotype	O
was	O
found	O
to	O
be	O
more	O
significantly	O
associated	O
with	O
TB	O
.	O

Allele	O
frequencies	O
for	O
guanine	O
(	O
G	O
)	O
and	O
A	O
were	O
found	O
to	O
be	O
0.95	O
and	O
0.05	O
in	O
the	O
control	O
group	O
and	O
0.86	O
and	O
0.14	O
in	O
the	O
TB	O
patient	O
group	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
developing	O
TB	O
disease	O
was	O
increased	O
6.04-	O
and	O
1.60-fold	O
for	O
carriers	O
of	O
the	O
AA	O
and	O
GA	O
genotypes	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
data	O
suggest	O
that	O
the	O
arginine	O
to	O
glutamine	O
substitution	O
at	O
residue	O
753	O
polymorphism	O
of	O
the	O
Toll	B
-	I
like	I
receptor	I
2	I
gene	O
influences	O
the	O
risk	O
of	O
developing	O
tuberculosis	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
MMP-1	B
promoter	O
is	O
correlated	O
with	O
histological	O
differentiation	O
of	O
gastric	O
cancer	O
.	O

PURPOSE	O
:	O
Matrix	B
metalloproteinase-1	I
(	O
MMP-1	B
)	O
plays	O
a	O
key	O
role	O
in	O
cancer	O
invasion	O
and	O
metastasis	O
by	O
degradation	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
and	O
basement	O
membrane	O
barriers	O
.	O

The	O
1G	O
/	O
2	O
G	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
the	O
MMP-1	B
promoter	O
at	O
position	O
-1607	O
bp	O
has	O
been	O
reported	O
to	O
affect	O
the	O
transcriptional	O
activity	O
.	O

In	O
the	O
light	O
of	O
these	O
findings	O
,	O
we	O
investigated	O
whether	O
this	O
SNP	O
in	O
the	O
MMP-1	B
promoter	O
is	O
associated	O
with	O
the	O
development	O
,	O
differentiation	O
,	O
and	O
progression	O
of	O
gastric	O
cancer	O
.	O

METHODS	O
:	O
The	O
215	O
gastric	O
cancer	O
patients	O
and	O
166	O
controls	O
were	O
used	O
in	O
this	O
study	O
.	O

The	O
SNP	O
of	O
the	O
MMP-1	B
promoter	O
was	O
analyzed	O
by	O
PCR	O
-	O
RFLP	O
and	O
sequencing	O
.	O

The	O
genotype	O
frequency	O
was	O
compared	O
between	O
cases	O
and	O
controls	O
,	O
and	O
the	O
association	O
with	O
clinicopathological	O
parameters	O
among	O
cases	O
was	O
studied	O
.	O

RESULTS	O
:	O
The	O
frequency	O
of	O
1G	O
/	O
2	O
G	O
genotypes	O
in	O
gastric	O
cancer	O
patients	O
was	O
similar	O
to	O
those	O
in	O
controls	O
(	O
p=0.57	O
)	O
.	O

The	O
degree	O
of	O
tumor	O
invasion	O
,	O
the	O
presence	O
of	O
lymph	O
node	O
metastasis	O
,	O
and	O
clinical	O
stage	O
showed	O
no	O
significant	O
association	O
with	O
the	O
SNP	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
found	O
a	O
significant	O
association	O
with	O
histological	O
differentiation	O
and	O
gender	O
among	O
gastric	O
cancer	O
patients	O
(	O
p<0.05	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
2	O
G	O
allele	O
in	O
the	O
MMP-1	B
promoter	O
did	O
not	O
enhance	O
the	O
risk	O
of	O
gastric	O
cancer	O
;	O
however	O
,	O
it	O
may	O
be	O
involved	O
in	O
differentiation	O
of	O
gastric	O
cancer	O
.	O

Association	O
of	O
the	O
T	O
-	O
cell	O
regulatory	O
gene	O
CTLA4	B
with	O
Graves	O
'	O
disease	O
and	O
autoimmune	O
thyroid	O
disease	O
in	O
the	O
Japanese	O
.	O

Autoimmune	O
thyroid	O
disease	O
(	O
AITD	O
)	O
is	O
caused	O
by	O
an	O
immune	O
response	O
to	O
self	O
-	O
thyroid	O
antigen	O
.	O

The	O
cytotoxic	B
T	I
-	I
lymphocyte	I
antigen-4	I
(	O
CTLA4	B
)	O
gene	O
,	O
encoding	O
a	O
negative	O
regulator	O
of	O
the	O
T	O
-	O
lymphocyte	O
immune	O
response	O
,	O
had	O
been	O
reported	O
to	O
be	O
associated	O
and/or	O
linked	O
to	O
AITD	O
.	O

Recently	O
,	O
AITD	O
susceptibility	O
in	O
the	O
Caucasians	O
was	O
mapped	O
to	O
the	O
6.1-kb	O
3'UTR	O
of	O
the	O
CTLA4	O
gene	O
,	O
in	O
which	O
the	O
three	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
CT60	O
,	O
JO31	O
,	O
and	O
JO30	O
were	O
strongly	O
associated	O
with	O
AITD	O
.	O

In	O
order	O
to	O
determine	O
the	O
association	O
of	O
the	O
CTLA4	B
gene	O
with	O
AITD	O
in	O
the	O
Japanese	O
,	O
case	O
-	O
control	O
association	O
analysis	O
for	O
the	O
four	O
SNPs	O
of	O
the	O
CTLA4	B
gene	O
using	O
380	O
AITD	O
patients	O
and	O
266	O
healthy	O
controls	O
was	O
done	O
.	O

Among	O
the	O
SNPs	O
examined	O
,	O
the	O
SNP	O
JO31	O
was	O
most	O
significantly	O
associated	O
with	O
AITD	O
in	O
the	O
Japanese	O
,	O
whereas	O
the	O
association	O
of	O
the	O
JO30	O
with	O
AITD	O
was	O
not	O
observed	O
.	O

The	O
frequency	O
of	O
the	O
disease	O
-	O
susceptible	O
G	O
allele	O
of	O
the	O
JO31	O
of	O
the	O
Japanese	O
control	O
was	O
higher	O
than	O
that	O
of	O
the	O
Caucasians	O
(	O
67.1	O
%	O
vs	O
50.2	O
%	O
)	O
;	O
however	O
,	O
the	O
G	O
allele	O
of	O
the	O
JO31	O
was	O
associated	O
with	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
(	O
67.1	O
%	O
vs	O
76.3	O
%	O
,	O
P=0.0013	O
)	O
and	O
AITD	O
in	O
the	O
Japanese	O
(	O
67.1	O
%	O
vs	O
74.2	O
%	O
,	O
P=0.0055	O
)	O
.	O

Furthermore	O
,	O
the	O
G	O
allele	O
of	O
the	O
JO31	O
was	O
associated	O
with	O
the	O
increased	O
risk	O
for	O
GD	O
[	O
P=0.0051	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
=1.7	O
]	O
and	O
AITD	O
(	O
P=0.016	O
,	O
OR=1.5	O
)	O
in	O
a	O
dominant	O
model	O
.	O

These	O
results	O
suggested	O
that	O
the	O
CTLA4	B
gene	O
is	O
involved	O
in	O
the	O
susceptibility	O
for	O
GD	O
and	O
AITD	O
in	O
the	O
Japanese	O
.	O

Fine	O
mapping	O
of	O
the	O
2p11	O
dyslexia	O
locus	O
and	O
exclusion	O
of	O
TACR1	B
as	O
a	O
candidate	O
gene	O
.	O

Developmental	O
dyslexia	O
,	O
or	O
reading	O
disability	O
,	O
is	O
a	O
multigenic	O
complex	O
disease	O
for	O
which	O
at	O
least	O
five	O
loci	O
,	O
i.e.	O
DYX1	B
-	I
3	I
and	O
DYX5	B
-	I
6	I
,	O
have	O
been	O
clearly	O
identified	O
from	O
the	O
human	O
genome	O
.	O

To	O
date	O
,	O
DYX1C1	B
is	O
the	O
only	O
dyslexia	O
candidate	O
gene	O
cloned	O
.	O

We	O
have	O
previously	O
reported	O
linkage	O
to	O
2p11	O
and	O
7q32	O
in	O
11	O
Finnish	O
pedigrees	O
.	O

Here	O
,	O
we	O
report	O
the	O
fine	O
mapping	O
of	O
the	O
approximately	O
40-cM	O
linked	O
region	O
from	O
chromosome	O
2	O
as	O
we	O
increased	O
marker	O
density	O
to	O
one	O
per	O
1.8	O
cM.	O
Linkage	O
was	O
supported	O
with	O
the	O
highest	O
NPL	O
score	O
of	O
3.0	O
(	O
P=0.001	O
)	O
for	O
marker	O
D2S2216	O
.	O

Association	O
analysis	O
using	O
the	O
six	O
pedigrees	O
showing	O
linkage	O
pointed	O
to	O
marker	O
D2S286	O
/	O
rs3220265	O
(	O
P	O
value	O
<	O
0.001	O
)	O
in	O
the	O
near	O
vicinity	O
of	O
D2S2216	O
.	O

We	O
went	O
on	O
to	O
further	O
characterise	O
this	O
approximately	O
15-cM	O
candidate	O
region	O
(	O
D2S2110-D2S2181	O
)	O
by	O
adding	O
six	O
SNPs	O
covering	O
approximately	O
670	O
kb	O
centred	O
at	O
D2S286	O
/	O
rs3220265	O
.	O

A	O
haplotype	O
pattern	O
could	O
no	O
longer	O
be	O
observed	O
in	O
this	O
region	O
,	O
which	O
was	O
therefore	O
excluded	O
from	O
the	O
candidate	O
area	O
.	O

This	O
also	O
excluded	O
the	O
TACR1	B
(	O
tachykinin	B
receptor	I
1	I
)	I
gene	I
,	I
located	I
at	I
marker	I
D2S286	I
.	O

The	O
dyslexia	O
candidate	O
region	O
on	O
2p11	O
is	O
,	O
therefore	O
,	O
now	O
limited	O
to	O
the	O
chromosomal	O
area	O
D2S2116-D2S2181	O
,	O
which	O
is	O
approximately	O
12	O
Mbp	O
of	O
human	O
sequence	O
and	O
is	O
at	O
a	O
distinct	O
location	O
from	O
the	O
previously	O
reported	O
DYX3	B
locus	O
,	O
raising	O
the	O
possibility	O
of	O
two	O
distinct	O
loci	O
on	O
chromosome	O
2p	O
.	O

Association	O
of	O
a	O
programmed	B
death	I
1	I
gene	O
polymorphism	O
with	O
the	O
development	O
of	O
rheumatoid	O
arthritis	O
,	O
but	O
not	O
systemic	O
lupus	O
erythematosus	O
.	O

OBJECTIVE	O
:	O
The	O
expression	O
of	O
autoimmunity	O
in	O
mice	O
deficient	O
in	O
programmed	B
death	I
1	I
(	O
PD-1	B
)	O
suggests	O
that	O
PD-1	B
is	O
a	O
candidate	O
gene	O
involved	O
in	O
the	O
development	O
of	O
human	O
autoimmune	O
diseases	O
such	O
as	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

We	O
therefore	O
tested	O
the	O
potential	O
association	O
between	O
PD-1	B
and	O
the	O
development	O
of	O
SLE	O
and	O
RA	O
by	O
conducting	O
case	O
-	O
control	O
genetic	O
-	O
association	O
studies	O
.	O

METHODS	O
:	O
Ninety	O
-	O
eight	O
SLE	O
patients	O
,	O
84	O
RA	O
patients	O
,	O
and	O
sex	O
-	O
matched	O
control	O
subjects	O
for	O
each	O
disease	O
group	O
were	O
recruited	O
and	O
genotyped	O
for	O
a	O
single	O
-	O
nucleotide	O
polymorphism	O
,	O
C+872	O
T	O
,	O
in	O
the	O
human	O
PD-1	B
gene	O
.	O

The	O
significance	O
of	O
the	O
association	O
of	O
the	O
PD-1	B
gene	O
with	O
SLE	O
or	O
with	O
RA	O
was	O
analyzed	O
by	O
statistical	O
tests	O
for	O
the	O
difference	O
in	O
genotype	O
distribution	O
between	O
disease	O
and	O
control	O
groups	O
.	O

RESULTS	O
:	O
The	O
human	O
PD-1	B
gene	O
was	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
disease	O
development	O
in	O
RA	O
patients	O
,	O
but	O
not	O
SLE	O
patients	O
.	O

The	O
risk	O
of	O
RA	O
development	O
appeared	O
to	O
be	O
significantly	O
increased	O
by	O
carriage	O
of	O
the	O
T	O
allele	O
(	O
odds	O
ratio	O
3.32	O
,	O
P	O
<	O
0.0001	O
)	O
or	O
the	O
C	O
/	O
T	O
genotype	O
(	O
odds	O
ratio	O
3.52	O
,	O
P	O
<	O
0.00005	O
)	O
.	O

CONCLUSION	O
:	O
The	O
PD-1	B
gene	O
is	O
significantly	O
associated	O
with	O
RA	O
susceptibility	O
,	O
suggesting	O
the	O
possibility	O
that	O
PD-1	B
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
RA	O
.	O

A	O
novel	O
A	O
/	O
G	O
SNP	O
in	O
the	O
-615th	O
position	O
of	O
the	O
dopamine	B
D4	I
receptor	I
promoter	O
region	O
as	O
a	O
source	O
of	O
misgenotyping	O
of	O
the	O
-616	O
C	O
/	O
G	O
SNP	O
.	O

The	O
polymorphic	O
5	O
'	O
upstream	O
region	O
of	O
the	O
dopamine	B
D4	I
receptor	I
(	O
DRD4	B
)	O
gene	O
containing	O
several	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
has	O
recently	O
become	O
a	O
focus	O
of	O
association	O
studies	O
in	O
psychiatric	O
genetics	O
.	O

Most	O
SNP	O
genotyping	O
methods	O
are	O
based	O
on	O
the	O
two	O
-	O
step	O
procedure	O
of	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
.	O

An	O
alternative	O
technique	O
is	O
a	O
single	O
-	O
step	O
method	O
of	O
allele	O
-	O
specific	O
amplification	O
(	O
ASA	O
)	O
,	O
previously	O
introduced	O
for	O
genotyping	O
the	O
-521	O
C	O
/	O
T	O
SNP	O
of	O
the	O
DRD4	B
promoter	O
region	O
and	O
applied	O
here	O
for	O
the	O
-616	O
C	O
/	O
G	O
SNP	O
.	O

Parallel	O
genotyping	O
of	O
individuals	O
with	O
the	O
novel	O
ASA	O
method	O
and	O
the	O
conventionally	O
used	O
Ava	O
II	O
RFLP	O
showed	O
a	O
potential	O
underestimation	O
of	O
the	O
-616	O
GG	O
genotype	O
frequency	O
by	O
the	O
conventional	O
method	O
.	O

Sequencing	O
the	O
dubious	O
samples	O
clearly	O
demonstrated	O
a	O
novel	O
A	O
/	O
G	O
SNP	O
at	O
the	O
-615th	O
position	O
influencing	O
the	O
Ava	O
II	O
digestion	O
and	O
thus	O
resulting	O
in	O
misgenotyping	O
.	O

To	O
avoid	O
this	O
problem	O
,	O
we	O
introduced	O
the	O
Sau96	O
I	O
RFLP	O
for	O
the	O
-616	O
C	O
/	O
G	O
genotyping	O
as	O
this	O
restriction	O
enzyme	O
is	O
not	O
sensitive	O
for	O
the	O
-615	O
A	O
/	O
G	O
sequence	O
variation	O
.	O

Allele	O
(	O
-616	O
G	O
=	O
0.48	O
;	O
-616	O
C	O
=	O
0.52	O
)	O
and	O
genotype	O
(	O
-616	O
GG	O
=	O
0.25	O
;	O
-616	O
GC	O
=	O
0.46	O
;	O
-616	O
CC	O
=	O
0.29	O
)	O
frequencies	O
were	O
determined	O
by	O
both	O
the	O
novel	O
ASA	O
and	O
the	O
Sau96	O
I	O
methods	O
.	O

The	O
obtained	O
genotype	O
frequencies	O
corresponded	O
to	O
the	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
in	O
our	O
healthy	O
Caucasian	O
sample	O
(	O
N	O
=	O
534	O
,	O
P	O
=	O
0.168	O
)	O
.	O

Using	O
these	O
methods	O
,	O
no	O
association	O
was	O
found	O
between	O
the	O
-616	O
C	O
/	O
G	O
SNP	O
and	O
personality	O
factors	O
of	O
Cloninger	O
's	O
temperament	O
and	O
character	O
inventory	O
(	O
N	O
=	O
153	O
)	O
in	O
our	O
population	O
.	O

C242	O
T	O
CYBA	B
polymorphism	O
of	O
the	O
NADPH	B
oxidase	I
is	O
associated	O
with	O
reduced	O
respiratory	O
burst	O
in	O
human	O
neutrophils	O
.	O

Oxidative	O
stress	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

p22phox	B
-	I
based	I
NAD	I
(	I
P	I
)	I
H	I
oxidases	I
exist	O
in	O
the	O
vessel	O
wall	O
,	O
acting	O
as	O
important	O
superoxide	O
-	O
generating	O
systems	O
in	O
the	O
vasculature	O
.	O

Some	O
studies	O
have	O
identified	O
reduced	O
atherosclerosis	O
in	O
the	O
presence	O
of	O
the	O
C242	O
T	O
CYBA	B
polymorphism	O
,	O
whereas	O
others	O
have	O
not	O
.	O

Because	O
vascular	O
p22phox	B
is	O
identical	O
to	O
neutrophil	O
p22phox	B
,	O
we	O
studied	O
the	O
association	O
between	O
the	O
C242	O
T	O
,	O
A640	O
G	O
,	O
and	O
-930A	O
/	O
G	O
CYBA	B
polymorphisms	O
and	O
the	O
quantity	O
of	O
superoxide	O
produced	O
from	O
neutrophils	O
isolated	O
from	O
healthy	O
adults	O
to	O
determine	O
if	O
these	O
polymorphisms	O
had	O
any	O
functional	O
impact	O
on	O
NADPH	B
oxidase	I
function	O
.	O

Neutrophils	O
were	O
isolated	O
from	O
90	O
subjects	O
by	O
Percoll	O
density	O
gradient	O
centrifugation	O
.	O

Genotypes	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
mapping	O
,	O
as	O
well	O
as	O
real	O
-	O
time	O
PCR	O
.	O

The	O
oxidative	O
burst	O
was	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

Superoxide	O
was	O
quantified	O
using	O
the	O
superoxide	B
dismutase	I
inhibitable	O
oxidation	O
of	O
the	O
spin	O
probe	O
hydroxylamine	O
1-hydroxy-3-carboxy	O
-	O
pyrrolidine	O
,	O
detected	O
by	O
electron	O
paramagnetic	O
resonance	O
.	O

Superoxide	O
production	O
was	O
significantly	O
affected	O
by	O
the	O
C242	O
T	O
polymorphism	O
,	O
being	O
8.7+	O
/	O
-0.7	O
,	O
7.9+	O
/	O
-0.6	O
,	O
and	O
5.9+	O
/	O
-1.2	O
micromol	O
/	O
L	O
per	O
minute	O
per	O
10	O
(	O
6	O
)	O
neutrophils	O
for	O
the	O
C242	O
T	O
CC	O
,	O
CT	O
,	O
and	O
TT	O
genotypes	O
,	O
respectively	O
(	O
P<0.05	O
)	O
.	O

In	O
contrast	O
,	O
the	O
A640	O
G	O
and	O
the	O
-930A	O
/	O
G	O
polymorphisms	O
did	O
not	O
alter	O
the	O
neutrophil	O
respiratory	O
burst	O
.	O

Phagocytic	O
respiratory	O
burst	O
activity	O
in	O
homozygous	O
individuals	O
with	O
the	O
T	O
allele	O
of	O
the	O
C242	O
T	O
CYBA	B
polymorphism	O
is	O
significantly	O
lower	O
than	O
of	O
wild	O
-	O
type	O
carriers	O
and	O
heterozygous	O
individuals	O
.	O

Because	O
p22phox	B
exists	O
in	O
both	O
the	O
neutrophil	O
and	O
vessel	O
wall	O
,	O
vascular	O
oxidative	O
stress	O
is	O
likely	O
diminished	O
in	O
individuals	O
with	O
this	O
polymorphism	O
.	O

Cytokines	O
and	O
chronic	O
rejection	O
:	O
a	O
study	O
in	O
kidney	O
transplant	O
long	O
-	O
term	O
survivors	O
.	O

BACKGROUND	O
:	O
In	O
part	O
,	O
the	O
long	O
-	O
term	O
survival	O
of	O
kidney	O
transplants	O
depends	O
on	O
the	O
efforts	O
to	O
perform	O
grafts	O
with	O
good	O
human	B
leukocyte	I
antigen	I
(	O
HLA	B
)	O
compatibility	O
,	O
but	O
there	O
are	O
other	O
mechanisms	O
that	O
must	O
induce	O
some	O
sort	O
of	O
tolerance	O
and	O
impair	O
the	O
anti	O
-	O
graft	O
immune	O
reaction	O
.	O

Because	O
cytokines	O
are	O
one	O
of	O
the	O
main	O
components	O
of	O
immune	O
response	O
,	O
we	O
evaluated	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
several	O
cytokine	O
genes	O
that	O
may	O
influence	O
the	O
production	O
of	O
a	O
given	O
cytokine	O
and	O
therefore	O
the	O
features	O
of	O
immune	O
reactions	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
416	O
first	O
cadaveric	O
kidney	O
transplants	O
were	O
monitored	O
for	O
HLA	B
matching	O
.	O

After	O
10	O
years	O
,	O
the	O
graft	O
was	O
still	O
functional	O
in	O
171	O
of	O
416	O
patients	O
;	O
102	O
of	O
171	O
patients	O
were	O
also	O
typed	O
for	O
cytokine	O
polymorphisms	O
.	O

RESULTS	O
:	O
The	O
mismatch	O
distributions	O
in	O
patients	O
who	O
underwent	O
transplantation	O
were	O
not	O
statistically	O
different	O
from	O
the	O
entire	O
group	O
of	O
patients	O
who	O
underwent	O
transplantation	O
during	O
the	O
same	O
time	O
period	O
.	O

Moreover	O
,	O
it	O
seems	O
that	O
almost	O
all	O
of	O
the	O
HLA	B
class	I
I	I
incompatible	O
long	O
-	O
term	O
survivors	O
are	O
homozygous	O
for	O
GG	O
at	O
the	O
-1082	O
interleukin	B
(	I
IL	I
)	I
-10	I
or	O
CC	O
at	O
the	O
-33IL4	O
.	O

CONCLUSIONS	O
:	O
We	O
observed	O
that	O
a	O
match	O
for	O
class	B
I	I
and	O
class	B
II	I
HLA	I
antigens	O
apparently	O
does	O
not	O
favor	O
the	O
long	O
-	O
term	O
survival	O
of	O
transplanted	O
kidneys	O
.	O

In	O
fact	O
,	O
matched	O
grafts	O
are	O
lost	O
before	O
10	O
years	O
in	O
the	O
same	O
proportion	O
as	O
the	O
mismatched	O
grafts	O
.	O

We	O
also	O
demonstrated	O
(	O
1	O
)	O
that	O
patients	O
who	O
are	O
homozygous	O
for	O
GG	O
at	O
the	O
SNP	O
-1082IL10	O
(	O
high	O
IL-10	B
producers	O
)	O
and	O
HLA	B
class	I
I	I
mismatched	O
(	O
but	O
matched	O
for	O
class	B
II	I
)	O
are	O
protected	O
from	O
chronic	O
rejection	O
,	O
and	O
(	O
2	O
)	O
that	O
patients	O
who	O
are	O
homozygous	O
for	O
CC	O
at	O
the	O
SNP	O
-33IL4	O
(	O
low	O
IL-4	B
producers	O
)	O
and	O
HLA	B
class	I
I	I
mismatched	O
(	O
regardless	O
of	O
matching	O
for	O
class	B
II	I
)	O
are	O
protected	O
from	O
chronic	O
rejection	O
.	O

Sequence	O
variants	O
of	O
toll	B
-	I
like	I
receptor	I
4	I
are	O
associated	O
with	O
prostate	O
cancer	O
risk	O
:	O
results	O
from	O
the	O
CAncer	O
Prostate	O
in	O
Sweden	O
Study	O
.	O

Inflammation	O
has	O
been	O
implicated	O
as	O
an	O
etiological	O
factor	O
in	O
several	O
human	O
cancers	O
.	O

Growing	O
evidence	O
suggests	O
that	O
chronic	O
inflammation	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
etiology	O
of	O
prostate	O
cancer	O
.	O

Considering	O
that	O
genetic	O
susceptibility	O
is	O
a	O
major	O
risk	O
factor	O
for	O
this	O
disease	O
,	O
we	O
hypothesize	O
that	O
sequence	O
variants	O
in	O
genes	O
that	O
regulate	O
inflammation	O
may	O
modify	O
individual	O
susceptibility	O
to	O
prostate	O
cancer	O
.	O

The	O
lipopolysaccharide	O
receptor	O
Toll	B
-	I
like	I
receptor	I
4	I
(	O
TLR4	B
)	O
is	O
a	O
central	O
player	O
in	O
the	O
signaling	O
pathways	O
of	O
the	O
innate	O
immune	O
response	O
to	O
infection	O
by	O
Gram	O
-	O
negative	O
bacteria	O
and	O
is	O
an	O
important	O
candidate	O
inflammatory	O
gene	O
.	O

We	O
performed	O
a	O
systematic	O
genetic	O
analysis	O
of	O
TLR4	B
sequence	O
variants	O
by	O
evaluating	O
eight	O
single	O
-	O
nucleotide	O
polymorphisms	O
that	O
span	O
the	O
entire	O
gene	O
among	O
1383	O
newly	O
diagnosed	O
prostate	O
cancer	O
patients	O
and	O
780	O
age-	O
and	O
residence	O
-	O
matched	O
controls	O
in	O
Sweden	O
.	O

We	O
found	O
an	O
association	O
between	O
a	O
sequence	O
variant	O
(	O
11381G	O
/	O
C	O
)	O
in	O
the	O
3'-untranslated	O
region	O
of	O
the	O
TLR4	B
gene	O
and	O
prostate	O
cancer	O
risk	O
.	O

The	O
frequency	O
of	O
the	O
variant	O
genotypes	O
(	O
CG	O
or	O
CC	O
)	O
was	O
significantly	O
higher	O
in	O
the	O
patients	O
(	O
24.1	O
%	O
)	O
than	O
in	O
the	O
controls	O
(	O
19.7	O
%	O
;	O
P	O
=	O
0.02	O
)	O
.	O

The	O
frequency	O
of	O
risk	O
genotypes	O
among	O
patients	O
diagnosed	O
before	O
the	O
age	O
of	O
65	O
years	O
was	O
even	O
higher	O
(	O
26.3	O
%	O
)	O
.	O

Compared	O
with	O
men	O
who	O
had	O
the	O
wild	O
-	O
type	O
genotype	O
of	O
this	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
GG	O
)	O
,	O
those	O
with	O
GC	O
or	O
CC	O
genotypes	O
had	O
a	O
26	O
%	O
increased	O
risk	O
for	O
prostate	O
cancer	O
(	O
odds	O
ratio	O
,	O
1.26	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.01	O
-	O
1.57	O
)	O
and	O
39	O
%	O
increased	O
risk	O
increased	O
risk	O
for	O
early	O
onset	O
prostate	O
cancer	O
(	O
before	O
age	O
65	O
years	O
;	O
odds	O
ratio	O
,	O
1.39	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.02	O
-	O
1.91	O
)	O
.	O

The	O
risk	O
attributable	O
to	O
this	O
variant	O
for	O
prostate	O
cancer	O
in	O
Sweden	O
was	O
estimated	O
to	O
be	O
4.9	O
%	O
.	O

Although	O
the	O
biological	O
mechanism	O
of	O
the	O
observed	O
association	O
remains	O
to	O
be	O
elucidated	O
,	O
our	O
finding	O
supports	O
a	O
role	O
for	O
a	O
bacteria	O
-	O
associated	O
response	O
pathway	O
,	O
possibly	O
acting	O
via	O
inflammation	O
,	O
in	O
the	O
development	O
of	O
prostate	O
cancer	O
.	O

No	O
genetic	O
association	O
between	O
tumour	B
necrosis	I
factor	I
receptor	I
II	I
196R	O
polymorphism	O
and	O
Japanese	O
sporadic	O
Alzheimer	O
's	O
disease	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
acute	O
effects	O
of	O
tumour	B
necrosis	I
factor	I
(	O
TNF	B
)	O
,	O
a	O
pro	O
-	O
inflammatory	O
cytokine	O
,	O
are	O
limited	O
by	O
binding	O
to	O
a	O
soluble	O
receptor	O
,	O
TNF	B
receptor	I
II	I
,	O
and	O
the	O
G	O
allele	O
at	O
position	O
196	O
in	O
exon	O
6	O
of	O
the	O
TNF	B
receptor	I
II	I
gene	O
(	O
TNFRII	B
196R	O
)	O
has	O
been	O
associated	O
with	O
auto	O
-	O
immune	O
diseases	O
.	O

Since	O
complex	O
interactions	O
among	O
cytokines	O
have	O
been	O
suggested	O
around	O
senile	O
plaques	O
in	O
Alzheimer	O
's	O
disease	O
,	O
TNF	B
might	O
be	O
associated	O
with	O
ageing	O
and	O
the	O
pathophysiology	O
of	O
Alzheimer	O
's	O
disease	O
.	O

We	O
examined	O
the	O
TNFRII	B
196R	O
polymorphism	O
in	O
243	O
Japanese	O
sporadic	O
Alzheimer	O
's	O
disease	O
cases	O
and	O
106	O
control	O
cases	O
using	O
a	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
.	O

Allelic	O
frequencies	O
with	O
TNFRII	B
196R	O
T	O
/	O
G	O
polymorphism	O
were	O
28.3	O
%	O
and	O
27.4	O
%	O
in	O
the	O
control	O
and	O
Alzheimer	O
's	O
disease	O
groups	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
no	O
genetic	O
association	O
between	O
TNFRII	B
196R	O
polymorphism	O
and	O
Alzheimer	O
's	O
disease	O
.	O

The	O
TNFRII	B
196R	O
G	O
allele	O
does	O
not	O
appear	O
to	O
be	O
associated	O
with	O
Alzheimer	O
's	O
disease	O
susceptibility	O
in	O
a	O
Japanese	O
population	O
.	O

Association	O
of	O
BDNF	B
with	O
anorexia	O
,	O
bulimia	O
and	O
age	O
of	O
onset	O
of	O
weight	O
loss	O
in	O
six	O
European	O
populations	O
.	O

Several	O
genes	O
with	O
an	O
essential	O
role	O
in	O
the	O
regulation	O
of	O
eating	O
behavior	O
and	O
body	O
weight	O
are	O
considered	O
candidates	O
involved	O
in	O
the	O
etiology	O
of	O
eating	O
disorders	O
(	O
ED	O
)	O
,	O
but	O
no	O
relevant	O
susceptibility	O
genes	O
with	O
a	O
major	O
effect	O
on	O
anorexia	O
nervosa	O
(	O
AN	O
)	O
or	O
bulimia	O
nervosa	O
(	O
BN	O
)	O
have	O
been	O
identified	O
.	O

Brain	B
-	I
derived	I
neurotrophic	I
factor	I
(	O
BDNF	B
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
and	O
body	O
weight	O
in	O
rodents	O
.	O

We	O
previously	O
reported	O
a	O
strong	O
association	O
of	O
the	O
Met66	O
allele	O
of	O
the	O
Val66Met	O
BDNF	B
variant	O
with	O
restricting	O
AN	O
(	O
ANR	O
)	O
and	O
low	O
minimum	O
body	O
mass	O
index	O
in	O
Spanish	O
patients	O
.	O

Another	O
single	O
nucleotide	O
polymorphism	O
located	O
in	O
the	O
promoter	O
region	O
of	O
the	O
BDNF	B
gene	O
(	O
-270C	O
>	O
T	O
)	O
showed	O
lack	O
of	O
association	O
with	O
any	O
ED	O
phenotype	O
.	O

In	O
order	O
to	O
replicate	O
these	O
findings	O
in	O
a	O
larger	O
sample	O
,	O
we	O
performed	O
a	O
case	O
-	O
control	O
study	O
in	O
1142	O
Caucasian	O
patients	O
with	O
ED	O
consecutively	O
recruited	O
in	O
six	O
different	O
centers	O
from	O
five	O
European	O
countries	O
(	O
France	O
,	O
Germany	O
,	O
Italy	O
,	O
Spain	O
and	O
UK	O
)	O
participating	O
in	O
the	O
'	O
Factors	O
in	O
Healthy	O
Eating	O
'	O
project	O
.	O

We	O
have	O
found	O
that	O
the	O
Met66	O
variant	O
is	O
strongly	O
associated	O
to	O
all	O
ED	O
subtypes	O
(	O
AN	O
,	O
ANR	O
,	O
binge	O
-	O
eating	O
/	O
purging	O
AN	O
and	O
BN	O
)	O
,	O
and	O
that	O
the	O
-270C	O
BDNF	B
variant	O
has	O
an	O
effect	O
on	O
BN	O
and	O
late	O
age	O
at	O
onset	O
of	O
weight	O
loss	O
.	O

These	O
are	O
the	O
first	O
two	O
variants	O
associated	O
with	O
the	O
pathophysiology	O
of	O
ED	O
in	O
different	O
populations	O
and	O
support	O
a	O
role	O
for	O
BDNF	B
in	O
the	O
susceptibility	O
to	O
aberrant	O
eating	O
behaviors	O
.	O

Fibroblast	B
growth	I
factor	I
20	I
polymorphisms	O
and	O
haplotypes	O
strongly	O
influence	O
risk	O
of	O
Parkinson	O
disease	O
.	O

The	O
pathogenic	O
process	O
responsible	O
for	O
the	O
loss	O
of	O
dopaminergic	O
neurons	O
within	O
the	O
substantia	O
nigra	O
of	O
patients	O
with	O
Parkinson	O
disease	O
(	O
PD	O
)	O
is	O
poorly	O
understood	O
.	O

Current	O
research	O
supports	O
the	O
involvement	O
of	O
fibroblast	B
growth	I
factor	I
(	O
FGF20	B
)	O
in	O
the	O
survival	O
of	O
dopaminergic	O
cells	O
.	O

FGF20	B
is	O
a	O
neurotrophic	O
factor	O
that	O
is	O
preferentially	O
expressed	O
within	O
the	O
substantia	O
nigra	O
of	O
rat	O
brain	O
.	O

The	O
human	O
homologue	O
has	O
been	O
mapped	O
to	O
8p21.3	O
-	O
8p22	O
,	O
which	O
is	O
within	O
an	O
area	O
of	O
PD	O
linkage	O
revealed	O
through	O
our	O
published	O
genomic	O
screen	O
.	O

To	O
test	O
whether	O
FGF20	B
influences	O
risk	O
of	O
PD	O
,	O
we	O
genotyped	O
five	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
lying	O
within	O
the	O
FGF20	B
gene	O
,	O
in	O
a	O
large	O
family	O
study	O
.	O

We	O
analyzed	O
our	O
sample	O
(	O
644	O
families	O
)	O
through	O
use	O
of	O
the	O
pedigree	O
disequilibrium	O
test	O
(	O
PDT	O
)	O
,	O
the	O
genotype	O
PDT	O
,	O
the	O
multilocus	O
-	O
genotype	O
PDT	O
,	O
and	O
the	O
family	O
-	O
based	O
association	O
test	O
to	O
assess	O
association	O
between	O
risk	O
of	O
PD	O
and	O
alleles	O
,	O
genotypes	O
,	O
multilocus	O
genotypes	O
,	O
and	O
haplotypes	O
.	O

We	O
discovered	O
a	O
highly	O
significant	O
association	O
of	O
PD	O
with	O
one	O
intronic	O
SNP	O
,	O
rs1989754	O
(	O
P=.0006	O
)	O
,	O
and	O
two	O
SNPs	O
,	O
rs1721100	O
(	O
P=.02	O
)	O
and	O
ss20399075	O
(	O
P=.0008	O
)	O
,	O
located	O
in	O
the	O
3	O
'	O
regulatory	O
region	O
in	O
our	O
overall	O
sample	O
.	O

Furthermore	O
,	O
we	O
detected	O
a	O
haplotype	O
(	O
A	O
-	O
G	O
-	O
C	O
-	O
C	O
-	O
T	O
)	O
that	O
is	O
positively	O
associated	O
with	O
risk	O
of	O
PD	O
(	O
P=.0003	O
)	O
,	O
whereas	O
a	O
second	O
haplotype	O
(	O
A	O
-	O
G	O
-	O
G	O
-	O
G	O
-	O
C	O
)	O
was	O
found	O
to	O
be	O
negatively	O
associated	O
with	O
risk	O
of	O
PD	O
(	O
P=.0009	O
)	O
.	O

Our	O
results	O
strongly	O
support	O
FGF20	B
as	O
a	O
risk	O
factor	O
for	O
PD	O
.	O

Polymorphisms	O
in	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
genes	O
and	O
skin	O
cancer	O
risk	O
.	O

UV	O
can	O
cause	O
a	O
wide	O
range	O
of	O
DNA	O
lesions	O
.	O

UVA	O
-	O
induced	O
oxidative	O
DNA	O
damage	O
and	O
blocked	O
DNA	O
replication	O
by	O
UVB	O
-	O
induced	O
photoproducts	O
can	O
lead	O
to	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
.	O

We	O
selected	O
11	O
haplotype	O
-	O
tagging	O
single	O
nucleotide	O
polymorphisms	O
in	O
three	O
DSB	O
repair	O
genes	O
XRCC2	B
,	O
XRCC3	B
,	O
and	O
LigaseIV	B
and	O
evaluated	O
their	O
associations	O
with	O
skin	O
cancer	O
risk	O
in	O
a	O
nested	O
case	O
-	O
control	O
study	O
within	O
the	O
Nurses	O
'	O
Health	O
Study	O
[	O
219	O
melanoma	O
,	O
286	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
,	O
300	O
basal	O
cell	O
carcinoma	O
(	O
BCC	O
)	O
,	O
and	O
873	O
controls	O
]	O
.	O

We	O
observed	O
that	O
the	O
XRCC3	B
18085	O
T	O
(	O
241Met	O
)	O
allele	O
and	O
its	O
associated	O
haplotype	O
were	O
significantly	O
inversely	O
associated	O
with	O
the	O
risks	O
of	O
SCC	O
and	O
BCC	O
,	O
whereas	O
the	O
XRCC3	B
4552C	O
allele	O
along	O
with	O
its	O
associated	O
haplotype	O
and	O
the	O
XRCC2	B
30833A	O
allele	O
were	O
significantly	O
associated	O
with	O
increased	O
BCC	O
risk	O
.	O

The	O
LigaseIV	B
4044	O
T	O
and	O
4062	O
T	O
alleles	O
were	O
associated	O
with	O
decreased	O
BCC	O
risk	O
;	O
two	O
of	O
four	O
haplotypes	O
were	O
significantly	O
associated	O
with	O
altered	O
BCC	O
risk	O
.	O

A	O
trend	O
toward	O
decreased	O
risk	O
of	O
nonmelanoma	O
skin	O
cancer	O
was	O
found	O
in	O
those	O
harboring	O
a	O
greater	O
number	O
of	O
putative	O
low	O
risk	O
alleles	O
(	O
P	O
for	O
trend	O
,	O
0.05	O
for	O
SCC	O
,	O
<	O
0.0001	O
for	O
BCC	O
)	O
.	O

The	O
main	O
effects	O
of	O
these	O
genotypes	O
were	O
essentially	O
null	O
for	O
melanoma	O
risk	O
.	O

This	O
study	O
provides	O
evidence	O
to	O
suggest	O
the	O
role	O
of	O
the	O
DSB	O
repair	O
pathway	O
in	O
skin	O
cancer	O
development	O
,	O
especially	O
for	O
BCC	O
.	O

Toll	B
-	I
like	I
receptor	I
2	I
Arg677Trp	O
polymorphism	O
is	O
associated	O
with	O
susceptibility	O
to	O
tuberculosis	O
in	O
Tunisian	O
patients	O
.	O

Toll	B
-	I
like	I
receptor	I
2	I
(	O
TLR2	B
)	O
is	O
critical	O
in	O
the	O
immune	O
response	O
to	O
mycobacteria	O
.	O

Herein	O
,	O
we	O
report	O
that	O
the	O
frequency	O
of	O
a	O
human	O
TLR2	B
Arg677Trp	O
polymorphism	O
(	O
C2029	O
T	O
nucleotide	O
substitution	O
)	O
in	O
tuberculosis	O
patients	O
in	O
Tunisia	O
is	O
significantly	O
higher	O
than	O
in	O
healthy	O
controls	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

This	O
finding	O
suggests	O
that	O
this	O
polymorphism	O
could	O
be	O
a	O
risk	O
factor	O
for	O
tuberculosis	O
.	O

Simple	O
and	O
rapid	O
detection	O
of	O
uncoupling	B
protein-2	I
-	O
866G	O
/	O
A	O
polymorphism	O
by	O
mutagenically	O
separated	O
polymerase	O
chain	O
reaction	O
.	O

BACKGROUND	O
:	O
Uncoupling	B
protein-2	I
(	O
UCP2	B
)	O
,	O
a	O
recently	O
identified	O
member	O
of	O
the	O
mitochondrial	O
transporter	O
superfamily	O
,	O
is	O
a	O
candidate	O
gene	O
for	O
obesity	O
.	O

A	O
common	O
G	O
/	O
A	O
polymorphism	O
in	O
the	O
UCP2	B
promoter	O
region	O
is	O
associated	O
with	O
enhanced	O
adipose	O
tissue	O
mRNA	O
expression	O
in	O
vivo	O
.	O

METHODS	O
:	O
We	O
developed	O
a	O
rapid	O
and	O
simple	O
method	O
,	O
mutagenically	O
separated	O
polymerase	O
chain	O
reaction	O
(	O
MS	O
-	O
PCR	O
)	O
for	O
genotyping	O
UCP2	B
-	O
866G	O
/	O
A	O
polymorphism	O
.	O

Two	O
reverse	O
mutagenic	O
allele	O
-	O
specific	O
primers	O
of	O
different	O
lengths	O
for	O
the	O
UCP2	B
-	O
866G	O
/	O
A	O
polymorphic	O
site	O
were	O
paired	O
with	O
the	O
same	O
forward	O
primer	O
in	O
the	O
same	O
PCR	O
reaction	O
.	O

RESULTS	O
:	O
Agarose	O
gel	O
electrophoresis	O
(	O
3.5	O
%	O
)	O
showed	O
at	O
least	O
one	O
of	O
the	O
two	O
allelic	O
products	O
and	O
provided	O
a	O
within	O
-	O
assay	O
quality	O
control	O
to	O
exclude	O
false	O
-	O
negative	O
results	O
.	O

The	O
203-bp	O
fragment	O
of	O
the	O
PCR	O
products	O
was	O
A	O
allele	O
-	O
specific	O
and	O
the	O
183-bp	O
fragment	O
was	O
G	O
allele	O
-	O
specific	O
.	O

The	O
frequencies	O
of	O
the	O
UCP2	B
-	O
866G	O
/	O
A	O
genotypes	O
in	O
72	O
Japanese	O
subjects	O
were	O
AA	O
:	O
21	O
(	O
29.2	O
%	O
)	O
,	O
AG	O
:	O
32	O
(	O
44.4	O
%	O
)	O
,	O
and	O
GG	O
:	O
19	O
(	O
26.4	O
%	O
)	O
.	O

The	O
results	O
were	O
confirmed	O
by	O
the	O
PCR	O
-	O
RFLP	O
genotyping	O
method	O
,	O
in	O
which	O
a	O
360-bp	O
fragment	O
of	O
PCR	O
products	O
was	O
cut	O
into	O
290-	O
and	O
70-bp	O
fragments	O
by	O
the	O
restriction	O
enzyme	O
MluI	O
when	O
the	O
G	O
allele	O
was	O
present	O
.	O

This	O
Japanese	O
group	O
showed	O
a	O
higher	O
frequency	O
of	O
the	O
AA	O
genotype	O
,	O
which	O
is	O
associated	O
with	O
a	O
low	O
prevalence	O
of	O
obesity	O
,	O
than	O
Caucasian	O
populations	O
.	O

CONCLUSIONS	O
:	O
The	O
MS	O
-	O
PCR	O
technique	O
is	O
a	O
simple	O
,	O
rapid	O
,	O
and	O
reliable	O
method	O
for	O
genotyping	O
UCP2	B
-	O
866G	O
/	O
A	O
polymorphism	O
.	O

The	O
allelic	O
variant	O
of	O
LAR	B
gene	O
promoter	O
-127	O
bp	O
T-->A	O
is	O
associated	O
with	O
reduced	O
risk	O
of	O
obesity	O
and	O
other	O
features	O
related	O
to	O
insulin	B
resistance	O
.	O

Insulin	B
resistance	O
,	O
which	O
is	O
pathogenic	O
for	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
,	O
is	O
under	O
the	O
control	O
of	O
largely	O
unknown	O
genetic	O
determinants	O
.	O

LAR	B
,	O
a	O
protein	O
-	O
tyrosine	O
phosphatase	O
which	O
inhibits	O
insulin	B
signalling	O
,	O
is	O
overexpressed	O
in	O
animal	O
and	O
human	O
models	O
of	O
insulin	B
resistance	O
.	O

We	O
studied	O
the	O
entire	O
sequence	O
of	O
the	O
LAR	B
gene	O
by	O
SSCP	O
analysis	O
and	O
automatic	O
DNA	O
sequencing	O
,	O
with	O
the	O
aim	O
of	O
verifying	O
whether	O
its	O
sequence	O
variants	O
might	O
be	O
associated	O
with	O
insulin	B
resistance	O
.	O

In	O
the	O
276	O
bp	O
sequence	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
(	O
i.e.	O
a	O
region	O
we	O
have	O
identified	O
as	O
having	O
basal	O
promoter	O
activity	O
)	O
a	O
-127	O
bp	O
T-->A	O
SNP	O
(	O
5	O
%	O
frequency	O
)	O
was	O
associated	O
with	O
lower	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
(	O
P=0.03	O
)	O
,	O
waist	O
circumference	O
(	O
P=0.01	O
)	O
,	O
blood	O
pressure	O
(	O
P=0.01	O
)	O
and	O
urinary	O
albumin	O
/	O
creatinine	O
ratio	O
(	O
P=0.04	O
)	O
in	O
589	O
non	O
-	O
diabetic	O
unrelated	O
individuals	O
from	O
the	O
Gargano	O
region	O
(	O
central	O
east	O
coast	O
of	O
Italy	O
)	O
.	O

To	O
quantify	O
the	O
risk	O
for	O
a	O
high	O
body	O
weight	O
conferred	O
by	O
the	O
-127	O
T-->A	O
SNP	O
,	O
the	O
whole	O
cohort	O
was	O
divided	O
into	O
tertiles	O
according	O
to	O
the	O
individual	O
BMI	O
.	O

The	O
risk	O
of	O
belonging	O
to	O
the	O
heavier	O
tertile	O
,	O
as	O
compared	O
to	O
the	O
leaner	O
one	O
,	O
was	O
reduced	O
by	O
approximately	O
60	O
%	O
.	O

In	O
a	O
population	O
from	O
East	O
Sicily	O
(	O
n=307	O
)	O
,	O
T	O
/	O
A	O
genotype	O
carriers	O
(	O
n=13	O
)	O
showed	O
lower	O
triglyceride	O
levels	O
(	O
P=0.04	O
)	O
and	O
higher	O
insulin	B
sensitivity	O
as	O
indicated	O
by	O
lower	O
plasma	O
glucose	O
(	O
P=0.03	O
)	O
and	O
serum	O
insulin	B
(	O
P=0.006	O
)	O
during	O
oral	O
glucose	O
tolerance	O
testing	O
(	O
OGTT	O
)	O
.	O

Promoter	O
activity	O
,	O
studied	O
by	O
cDNA	O
transfection	O
experiments	O
,	O
was	O
similar	O
for	O
the	O
A	O
and	O
T	O
alleles	O
.	O

In	O
conclusion	O
,	O
a	O
genetic	O
variant	O
of	O
the	O
LAR	B
gene	O
promoter	O
is	O
consistently	O
associated	O
with	O
features	O
of	O
insulin	B
resistance	O
in	O
two	O
different	O
Caucasian	O
populations	O
.	O

Although	O
the	O
biological	O
relevance	O
of	O
this	O
variant	O
has	O
yet	O
to	O
be	O
determined	O
,	O
this	O
finding	O
underlines	O
the	O
potential	O
importance	O
of	O
the	O
LAR	B
gene	O
in	O
dysregulation	O
of	O
insulin	B
sensitivity	O
and	O
related	O
disorders	O
.	O

Evaluation	O
of	O
the	O
role	O
of	O
the	O
SQSTM1	B
gene	O
in	O
sporadic	O
Belgian	O
patients	O
with	O
Paget	O
's	O
disease	O
.	O

A	O
positional	O
cloning	O
effort	O
in	O
French	O
Canadian	O
families	O
with	O
Paget	O
's	O
disease	O
of	O
bone	O
(	O
PDB	O
)	O
resulted	O
in	O
the	O
identification	O
of	O
a	O
mutation	O
in	O
the	O
sequestosome1	B
(	O
SQSTM1	B
)	O
gene	O
in	O
a	O
subset	O
of	O
both	O
familial	O
and	O
sporadic	O
PDB	O
cases	O
.	O

This	O
was	O
confirmed	O
in	O
samples	O
of	O
mainly	O
United	O
Kingdom	O
(	O
UK	O
)	O
origin	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
both	O
mutation	O
analysis	O
and	O
association	O
studies	O
in	O
order	O
to	O
evaluate	O
the	O
role	O
of	O
this	O
gene	O
in	O
a	O
collection	O
of	O
isolated	O
Belgian	O
PDB	O
patients	O
.	O

A	O
mutation	O
in	O
the	O
SQSTM1	B
gene	O
was	O
found	O
in	O
only	O
6	O
of	O
111	O
patients	O
(	O
5.4	O
%	O
)	O
.	O

In	O
all	O
cases	O
it	O
involves	O
the	O
P392L	O
mutation	O
,	O
previously	O
shown	O
to	O
be	O
common	O
in	O
both	O
familial	O
and	O
sporadic	O
cases	O
.	O

To	O
perform	O
association	O
studies	O
,	O
we	O
selected	O
8	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
looked	O
for	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
between	O
these	O
.	O

Haplotype	O
analysis	O
indicated	O
that	O
typing	O
of	O
3	O
Tag	O
SNPs	O
(	O
IVS1	O
+	O
633A	O
/	O
C	O
,	O
IVS5	O
-	O
23A	O
/	O
G	O
,	O
and	O
976A	O
/	O
G	O
)	O
enables	O
us	O
to	O
identify	O
the	O
most	O
common	O
haplotypes	O
.	O

Association	O
studies	O
for	O
the	O
3	O
selected	O
SNPs	O
,	O
based	O
on	O
105	O
PDB	O
cases	O
without	O
a	O
SQSTM1	B
mutation	O
and	O
159	O
control	O
individuals	O
,	O
did	O
not	O
support	O
a	O
possible	O
influence	O
of	O
natural	O
variants	O
in	O
the	O
SQSTM1	B
gene	O
either	O
on	O
the	O
pathogenesis	O
of	O
PDB	O
or	O
on	O
the	O
disease	O
severity	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
confirms	O
that	O
the	O
P392L	O
mutation	O
is	O
a	O
recurrent	O
mutation	O
causing	O
PDB	O
in	O
different	O
populations	O
.	O

We	O
were	O
not	O
able	O
to	O
show	O
an	O
association	O
between	O
SQSTM1	B
polymorphisms	O
and	O
PDB	O
in	O
our	O
population	O
but	O
this	O
clearly	O
needs	O
to	O
be	O
extended	O
to	O
other	O
populations	O
.	O

The	O
presented	O
identification	O
of	O
haplotype	O
Tag	O
SNPs	O
will	O
be	O
of	O
major	O
help	O
for	O
such	O
studies	O
.	O

Association	O
of	O
single	O
nucleotide	O
polymorphisms	O
within	O
cytokine	O
genes	O
with	O
juvenile	O
idiopathic	O
arthritis	O
in	O
the	O
Czech	O
population	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
possible	O
association	O
of	O
juvenile	O
idiopathic	O
arthritis	O
(	O
JIA	O
)	O
with	O
polymorphisms	O
within	O
cytokine	O
genes	O
in	O
the	O
Czech	O
population	O
.	O

METHODS	O
:	O
In	O
a	O
case	O
-	O
control	O
study	O
,	O
genotypes	O
of	O
130	O
patients	O
with	O
JIA	O
(	O
63	O
male	O
,	O
67	O
female	O
;	O
age	O
at	O
onset	O
7.6	O
+	O
/-	O

4.4	O
yrs	O
;	O
43	O
oligoarticular	O
,	O
72	O
polyarticular	O
,	O
15	O
systemic	O
form	O
)	O
were	O
compared	O
to	O
102	O
healthy	O
unrelated	O
blood	O
donors	O
.	O

Using	O
the	O
polymerase	O
chain	O
reaction	O
technique	O
with	O
sequence	O
-	O
specific	O
primers	O
from	O
the	O
13th	O
IHWG	O
workshop	O
,	O
we	O
analyzed	O
19	O
single	O
nucleotide	O
polymorphisms	O
within	O
12	O
different	O
cytokine	O
genes	O
[	O
interleukin	B
(	I
IL	I
)	I
-1a	I
,	O
IL-1beta	B
,	O
IL-2	B
,	O
IL-4	B
,	O
IL-6	B
,	O
IL-10	B
,	O
IL-12	B
,	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-beta	I
,	O
interferon	B
(	I
IFN	I
)	I
-g	I
]	O
,	O
and	O
related	O
molecules	O
(	O
IL-1R	B
,	O
IL-1RA	B
,	O
IL-4Ra	B
)	O
.	O

Genotype	O
frequencies	O
were	O
compared	O
using	O
chi	O
-	O
square	O
analysis	O
,	O
and	O
the	O
significance	O
level	O
was	O
corrected	O
for	O
the	O
number	O
of	O
independent	O
tests	O
.	O

RESULTS	O
:	O
Significant	O
positive	O
association	O
was	O
found	O
for	O
the	O
G	O
allele	O
of	O
the	O
IL-4	B
-1098	O
T	O
/	O
G	O
polymorphism	O
,	O
which	O
was	O
carried	O
by	O
10	O
%	O
of	O
cases	O
and	O
25	O
%	O
of	O
controls	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
0.32	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.16	O
-	O
0.67	O
,	O
corrected	O
p	O
=	O
0.038	O
)	O
.	O

Also	O
,	O
a	O
nonsignificant	O
increase	O
in	O
the	O
frequency	O
of	O
the	O
IL-1beta	B
+	O
3962	O
C	O
allele	O
was	O
detected	O
in	O
cases	O
(	O
96	O
%	O
)	O
versus	O
controls	O
(	O
84	O
%	O
)	O
(	O
OR	O
4.65	O
,	O
95	O
%	O
CI	O
1.64	O
-	O
13.2	O
,	O
corrected	O
p	O
=	O
0.091	O
)	O
.	O

We	O
did	O
not	O
replicate	O
previously	O
found	O
associations	O
with	O
the	O
IL-1a	B
,	O
IL-6	B
,	O
IL-10	B
,	O
and	O
IL-1RIL-1RA	B
polymorphisms	O
.	O

CONCLUSION	O
:	O
Our	O
study	O
showed	O
association	O
with	O
JIA	O
for	O
the	O
IL-4	B
-1098	O
T	O
/	O
G	O
polymorphism	O
.	O

It	O
also	O
underlines	O
the	O
genetic	O
contribution	O
of	O
IL-1	B
polymorphisms	O
to	O
the	O
pathogenesis	O
of	O
JIA	O
,	O
as	O
another	O
polymorphism	O
within	O
the	O
IL-1beta	B
may	O
influence	O
the	O
risk	O
of	O
the	O
disease	O
.	O

